# **CLH report**

# **Proposal for Harmonised Classification and Labelling**

## Based on Regulation (EC) No 1272/2008 (CLP Regulation), Annex VI, Part 2

# **Substance Name: Decanoic acid**

EC Number: 206-376-4

CAS Number: 334-48-5

Index Number:

Contact details for dossier submitter:

**Umweltbundesamt GmbH** 

on behalf of

#### **AT Competent Authority**

Federal Ministry of Agriculture, Forestry, Environment and Water Management

Version number: 2

**Date: 4 June 2012** 

# CONTENTS

# Part A.

1	PROPOSAL FOR HARMONISED CLASSIFICATION AND LABELLING	6
	1.1 SUBSTANCE	6
	1.2 HARMONISED CLASSIFICATION AND LABELLING PROPOSAL	6
	TABLE 2:       THE CURRENT ANNEX VI ENTRY AND THE PROPOSED HARMONISED CLASSIFICATION	6
	PROPOSED HARMONISED CLASSIFICATION AND LABELLING BASED ON CLP REGULATION AND/OR DSD CRITERIA	8
	2.1 HISTORY OF THE PREVIOUS CLASSIFICATION AND LABELLING	12
	2.2 SHORT SUMMARY OF THE SCIENTIFIC JUSTIFICATION FOR THE CLH PROPOSAL	12
	2.3 CURRENT HARMONISED CLASSIFICATION AND LABELLING	13
	2.3.1 Current classification and labelling in Annex VI, Table 3.1 in the CLP Regulation	13
	2.3.2 Current classification and labelling in Annex VI, Table 3.2 in the CLP Regulation	13
	2.4 CURRENT SELF-CLASSIFICATION AND LABELLING	13
	2.4.1 Current self-classification and labelling based on the CLP Regulation criteria	13
	2.4.2 Current self-classification and labelling based on DSD criteria	13
3	JUSTIFICATION THAT ACTION IS NEEDED AT COMMUNITY LEVEL	14
S	CIENTIFIC EVALUATION OF THE DATA	14
1	IDENTITY OF THE SUBSTANCE	14
	1.1 NAME AND OTHER IDENTIFIERS OF THE SUBSTANCE	14
	1.2 COMPOSITION OF THE SUBSTANCE	
	1.2.1 Composition of test material	15
	1.3 PHYSICO-CHEMICAL PROPERTIES	15
2	MANUFACTURE AND USES	18
		10
	2.1 MANUFACTURE	10 18
	2.2 IDENTIFIED USES	10
3	CLASSIFICATION FOR PHYSICO-CHEMICAL PROPERTIES	19
	3.1 All hazard classes	19
	3.1.1 Summary and discussion of all hazard classes	19
	3.1.2 Comparison with criteria	19
	3.1.3 Conclusions on classification and labelling	20
4	HUMAN HEALTH HAZARD ASSESSMENT	20
	4.1 TOXICOKINETICS (ABSORPTION, METABOLISM, DISTRIBUTION AND ELIMINATION)	20
	4.1.1 Non-human information	22
	4.1.2 Human information	22
	4.1.3 Summary and discussion on toxicokinetics	22
	4.2 ACUTE TOXICITY	22
	4.2.1 Non-human information	22
	4.2.1.1 Acute toxicity: oral	22
	4.2.1.2 Acute toxicity: inhalation	22
	4.2.1.3 Acute toxicity: dermal	23
	4.2.1.4 Acute toxicity: other information	24
	4.2.2 Fluman information	24
	4.2.5 Summary and alscussion of acute toxicity	24
	4.2.4 Comparison with criteria	24
	4.2.3 Conclusions on classification and labelling	24
	4.5 SPECIFIC TAKUET UKUAN TUATULT I – SINGLE EXPUSURE (STUT SE)	24 25
	4.4.1 Skin irritation	25 25
		25

4.4.1.	Human information	
4.4.1.2	Non-human information	
4.4.1.3	Summary and discussion of skin irritation	
4.4.1.4	Threshold for acute dermal irritation	31
4.4.1.5	Comparison with criteria	
4.4.1.6	Conclusions on classification and labelling	
4.4.2	Eye irritation	
4.4.2.1	Non-human information	
4.4.2.2	Human information	
4.4.2.3	Summary and discussion of eye irritation	
4.4.2.4	Comparison with criteria	34
4.4.2.5	Conclusions on classification and labelling	34
4.4.3	Respiratory tract irritation	34
4.4.3.1	Non-human information	34
4.4.3.2	Human information	34
4.4.3.3	Summary and discussion of respiratory tract irritation	
4.4.3.4	Comparison with criteria	
4.4.3.5	Conclusions on classification and labelling	
4.5 CC	RROSIVITY	
4.6 SE	NSITISATION	36
4.6.1	Skin sensititsation	36
4.6.1.1	Non-human information	36
4.6.1.2	Human information	36
4.6.1.3	Summary and discussion of skin sensitisation	36
4.6.1.4	Comparison with criteria	
4.6.1.5	Conclusions on classification and labelling	
4.6.2	Respiratory sensitisation	
4.7 Re	PEATED DOSE TOXICITY	
4.7.1	Non-human information	<i>3</i> 8
4.7.2	Human information	41
4.7.3	Summary and Discussion of repeated dose toxicity	41
4.7.4	Other relevant information	
175		
4.7.5	Summary and discussion of repeated dose toxicity findings relevant for classification accordi	ing to DSD
4.7.5	Summary and discussion of repeated dose toxicity findings relevant for classification accordi 43	ing to DSD
4.7.5 4.7.6	Summary and discussion of repeated dose toxicity findings relevant for classification accordi 43 Comparison with criteria of repeated dose toxicity findings relevant for classification accord	ing to DSD
4.7.5 4.7.6	Summary and discussion of repeated dose toxicity findings relevant for classification accordi 43 Comparison with criteria of repeated dose toxicity findings relevant for classification accord 43	ing to DSD ling to DSD
4.7.5 4.7.6 4.7.7	Summary and discussion of repeated dose toxicity findings relevant for classification accordi 43 Comparison with criteria of repeated dose toxicity findings relevant for classification accord 43 Conclusions on classification and labelling of repeated dose toxicity findings relevant for cla	ing to DSD ling to DSD essification
4.7.5 4.7.6 4.7.7 accordin	Summary and discussion of repeated dose toxicity findings relevant for classification accordi 43 Comparison with criteria of repeated dose toxicity findings relevant for classification accord 43 Conclusions on classification and labelling of repeated dose toxicity findings relevant for cla 9 to DSD	ing to DSD ling to DSD essification 43
4.7.5 4.7.6 4.7.7 accordin 4.8 SP	Summary and discussion of repeated dose toxicity findings relevant for classification accordi 43 Comparison with criteria of repeated dose toxicity findings relevant for classification accord 43 Conclusions on classification and labelling of repeated dose toxicity findings relevant for cla g to DSD	ing to DSD ling to DSD ussification 
4.7.5 4.7.6 4.7.7 <i>accordin</i> 4.8 SP	Summary and discussion of repeated dose toxicity findings relevant for classification accordi 43 Comparison with criteria of repeated dose toxicity findings relevant for classification accord 43 Conclusions on classification and labelling of repeated dose toxicity findings relevant for cla g to DSD ECIFIC TARGET ORGAN TOXICITY (CLP REGULATION) – REPEATED EXPOSURE (STOT RE)	ing to DSD ling to DSD ussification 
4.7.5 4.7.6 4.7.7 accordin 4.8 SP 4.9 GE	Summary and discussion of repeated dose toxicity findings relevant for classification accordi 43 Comparison with criteria of repeated dose toxicity findings relevant for classification accord 43 Conclusions on classification and labelling of repeated dose toxicity findings relevant for cla g to DSD ECIFIC TARGET ORGAN TOXICITY (CLP REGULATION) – REPEATED EXPOSURE (STOT RE) RM CELL MUTAGENICITY (MUTAGENICITY)	ing to DSD ling to DSD ussification 43 43 44
4.7.5 4.7.6 4.7.7 accordin 4.8 SP 4.9 GE 4.9.1	Summary and discussion of repeated dose toxicity findings relevant for classification accordi 43 Comparison with criteria of repeated dose toxicity findings relevant for classification accord 43 Conclusions on classification and labelling of repeated dose toxicity findings relevant for cla g to DSD ECIFIC TARGET ORGAN TOXICITY (CLP REGULATION) – REPEATED EXPOSURE (STOT RE) RM CELL MUTAGENICITY (MUTAGENICITY)	ing to DSD ling to DSD ussification 43 43 44 44
4.7.5 4.7.6 4.7.7 <i>accordin</i> 4.8 SP 4.9 Ge 4.9.1 4.9.1.1	Summary and discussion of repeated dose toxicity findings relevant for classification accordi 43 Comparison with criteria of repeated dose toxicity findings relevant for classification accord 43 Conclusions on classification and labelling of repeated dose toxicity findings relevant for cla g to DSD ECIFIC TARGET ORGAN TOXICITY (CLP REGULATION) – REPEATED EXPOSURE (STOT RE) RM CELL MUTAGENICITY (MUTAGENICITY) Non-human information In vitro data	ing to DSD ling to DSD ssification 43 44 44 44 44
4.7.5 4.7.6 4.7.7 <i>accordin</i> 4.8 SP 4.9 GE 4.9.1 4.9.1.1 4.9.1.2 4.9.2	Summary and discussion of repeated dose toxicity findings relevant for classification accordi 43 Comparison with criteria of repeated dose toxicity findings relevant for classification accord 43 Conclusions on classification and labelling of repeated dose toxicity findings relevant for cla g to DSD ECIFIC TARGET ORGAN TOXICITY (CLP REGULATION) – REPEATED EXPOSURE (STOT RE) RM CELL MUTAGENICITY (MUTAGENICITY) Non-human information In vivo data	ing to DSD ling to DSD ssification 43 43 44 44 44 44 45
4.7.5 4.7.6 4.7.7 <i>accordin</i> 4.8 SP 4.9 GE 4.9.1 4.9.1.1 4.9.1.2 4.9.2 4.0.3	Summary and discussion of repeated dose toxicity findings relevant for classification accordi 43 Comparison with criteria of repeated dose toxicity findings relevant for classification accord 43 Conclusions on classification and labelling of repeated dose toxicity findings relevant for cla g to DSD ECIFIC TARGET ORGAN TOXICITY (CLP REGULATION) – REPEATED EXPOSURE (STOT RE) RM CELL MUTAGENICITY (MUTAGENICITY) Non-human information In vitro data Human information	ing to DSD ling to DSD essification 43 43 44 44 44 45 45
4.7.5 4.7.6 4.7.7 <i>accordin</i> 4.8 SP 4.9 GE 4.9.1 4.9.1.1 4.9.1.2 4.9.2 4.9.3	Summary and discussion of repeated dose toxicity findings relevant for classification accordi 43 Comparison with criteria of repeated dose toxicity findings relevant for classification accord 43 Conclusions on classification and labelling of repeated dose toxicity findings relevant for cla g to DSD ECIFIC TARGET ORGAN TOXICITY (CLP REGULATION) – REPEATED EXPOSURE (STOT RE) RM CELL MUTAGENICITY (MUTAGENICITY) Non-human information In vitro data In vitro data Human information	ing to DSD ling to DSD essification 43 44 44 44 44 45 45 45 46
4.7.5 4.7.6 4.7.7 accordin 4.8 SP 4.9 GE 4.9.1 4.9.1.1 4.9.1.2 4.9.2 4.9.3 4.9.4	Summary and discussion of repeated dose toxicity findings relevant for classification accordi 43 Comparison with criteria of repeated dose toxicity findings relevant for classification accord 43 Conclusions on classification and labelling of repeated dose toxicity findings relevant for cla g to DSD ECIFIC TARGET ORGAN TOXICITY (CLP REGULATION) – REPEATED EXPOSURE (STOT RE) RM CELL MUTAGENICITY (MUTAGENICITY) Non-human information In vitro data In vitro data Human information Other relevant information of mutagenicity	ing to DSD ling to DSD essification 43 43 44 44 44 44 44 45 45 45 46 46
4.7.5 4.7.6 4.7.7 accordin 4.8 SP 4.9 GE 4.9.1 4.9.1.1 4.9.1.2 4.9.2 4.9.3 4.9.4 4.9.5	Summary and discussion of repeated dose toxicity findings relevant for classification accordi 43 Comparison with criteria of repeated dose toxicity findings relevant for classification accord 43 Conclusions on classification and labelling of repeated dose toxicity findings relevant for cla g to DSD ECIFIC TARGET ORGAN TOXICITY (CLP REGULATION) – REPEATED EXPOSURE (STOT RE) RM CELL MUTAGENICITY (MUTAGENICITY) Non-human information In vitro data In vitro data	ing to DSD ling to DSD essification 43 43 44 44 44 44 44 45 45 45 46 46 46
4.7.5 4.7.6 4.7.7 accordin 4.8 SP 4.9 GE 4.9.1 4.9.1.1 4.9.1.2 4.9.2 4.9.3 4.9.4 4.9.5 4.9.6	Summary and discussion of repeated dose toxicity findings relevant for classification accordi 43 Comparison with criteria of repeated dose toxicity findings relevant for classification accord 43 Conclusions on classification and labelling of repeated dose toxicity findings relevant for cla g to DSD ECIFIC TARGET ORGAN TOXICITY (CLP REGULATION) – REPEATED EXPOSURE (STOT RE) RM CELL MUTAGENICITY (MUTAGENICITY) Non-human information In vitro data In vitro data Human information Other relevant information Summary and discussion of mutagenicity Comparison with criteria Conclusions on classification and labelling	ing to DSD ling to DSD essification 43 43 44 44 44 44 44 44 45 45 46 46 46 46
4.7.5 4.7.6 4.7.7 accordin 4.8 SP 4.9 GE 4.9.1 4.9.1.1 4.9.1.2 4.9.2 4.9.3 4.9.4 4.9.5 4.9.6 4.10 CA	Summary and discussion of repeated dose toxicity findings relevant for classification accordi 43 Comparison with criteria of repeated dose toxicity findings relevant for classification accord 43 Conclusions on classification and labelling of repeated dose toxicity findings relevant for cla g to DSD ECIFIC TARGET ORGAN TOXICITY (CLP REGULATION) – REPEATED EXPOSURE (STOT RE) RM CELL MUTAGENICITY (MUTAGENICITY) Non-human information In vitro data Human information Other relevant information Summary and discussion of mutagenicity Comparison with criteria Conclusions on classification and labelling RCINOGENICITY	ing to DSD ling to DSD essification 43 43 44 44 44 44 44 44 45 46 46 46 46 46 46 46
4.7.5 4.7.6 4.7.7 accordin 4.8 SP 4.9 GE 4.9.1 4.9.1.1 4.9.1.2 4.9.2 4.9.3 4.9.4 4.9.5 4.9.6 4.10 CA 4.10.1	Summary and discussion of repeated dose toxicity findings relevant for classification accordi 43 Comparison with criteria of repeated dose toxicity findings relevant for classification accord 43 Conclusions on classification and labelling of repeated dose toxicity findings relevant for cla g to DSD ECIFIC TARGET ORGAN TOXICITY (CLP REGULATION) – REPEATED EXPOSURE (STOT RE) RM CELL MUTAGENICITY (MUTAGENICITY) Non-human information In vitro data Human information Other relevant information formation Summary and discussion of mutagenicity Comparison with criteria Conclusions on classification and labelling RCINOGENICITY Non-human information	ing to DSD ling to DSD essification 43 43 44 44 44 44 44 44 45 45 46 46 46 46 46 46 46 46 46 46 46 46
4.7.5 4.7.6 4.7.7 accordin 4.8 SP 4.9 GE 4.9.1 4.9.1.1 4.9.1.2 4.9.2 4.9.3 4.9.4 4.9.5 4.9.6 4.10 CA 4.10.1 4.10.2	Summary and discussion of repeated dose toxicity findings relevant for classification accordi 43 Comparison with criteria of repeated dose toxicity findings relevant for classification accord 43 Conclusions on classification and labelling of repeated dose toxicity findings relevant for cla g to DSD	ing to DSD ling to DSD essification 43 43 44 44 44 44 44 44 45 45 46 46 46 46 46 46 46 46 46 46 46 46 47
4.7.5 4.7.6 4.7.7 accordin 4.8 SP 4.9 GE 4.9.1 4.9.1.1 4.9.1.2 4.9.2 4.9.3 4.9.4 4.9.5 4.9.4 4.9.5 4.9.6 4.10 CA 4.10.1 4.10.2 4.10.3	Summary and discussion of repeated dose toxicity findings relevant for classification accordi 43 Comparison with criteria of repeated dose toxicity findings relevant for classification accord 43 Conclusions on classification and labelling of repeated dose toxicity findings relevant for cla g to DSD	ing to DSD ling to DSD ssification 43 43 44 44 44 44 44 44 45 45 46 46 46 46 46 46 46 46 46 46 47 47
4.7.5 4.7.6 4.7.7 accordin 4.8 SP 4.9 GE 4.9.1 4.9.1.1 4.9.1.2 4.9.2 4.9.3 4.9.4 4.9.5 4.9.6 4.10 CA 4.10.1 4.10.2 4.10.3 4.10.4	Summary and discussion of repeated dose toxicity findings relevant for classification accordi 43 Comparison with criteria of repeated dose toxicity findings relevant for classification accord 43 Conclusions on classification and labelling of repeated dose toxicity findings relevant for cla g to DSD ECIFIC TARGET ORGAN TOXICITY (CLP REGULATION) – REPEATED EXPOSURE (STOT RE) RM CELL MUTAGENICITY (MUTAGENICITY) Non-human information In vitro data In vitro data <i>Other relevant information</i> Summary and discussion of mutagenicity Comparison with criteria Conclusions on classification and labelling RCINOGENICITY Non-human information Summary and discussion of carcinogenicity Comparison with criteria Comparison with criteria Non-human information Summary and discussion of carcinogenicity Comparison with criteria Non-human information Summary and discussion of carcinogenicity Comparison with criteria	ing to DSD ling to DSD ssification 43 43 44 44 44 44 44 44 45 46 46 46 46 46 46 46 46 46 47 47 47 47
4.7.5 4.7.6 4.7.7 accordin 4.8 SP 4.9 GE 4.9.1 4.9.1.1 4.9.1.2 4.9.2 4.9.3 4.9.4 4.9.5 4.9.6 4.10 CA 4.10.1 4.10.2 4.10.3 4.10.4 4.10.5	Summary and discussion of repeated dose toxicity findings relevant for classification accordi 43 Comparison with criteria of repeated dose toxicity findings relevant for classification accord 43 Conclusions on classification and labelling of repeated dose toxicity findings relevant for cla g to DSD	ing to DSD ling to DSD ssification 43 43 44 44 44 44 44 44 45 46 46 46 46 46 46 46 46 46 47 47 47 47 47 47
4.7.5 4.7.6 4.7.7 accordin 4.8 SP 4.9 GE 4.9.1 4.9.1.1 4.9.1.2 4.9.2 4.9.3 4.9.4 4.9.5 4.9.6 4.10 CA 4.10.1 4.10.2 4.10.3 4.10.4 4.10.5 4.11 TC	Summary and discussion of repeated dose toxicity findings relevant for classification accordi 43 Comparison with criteria of repeated dose toxicity findings relevant for classification accord 43 Conclusions on classification and labelling of repeated dose toxicity findings relevant for cla g to DSD	ing to DSD ling to DSD ssification 43 43 44 44 44 44 44 44 45 46 46 46 46 46 46 46 46 46 47 47 47 47 47 47 47 47 47
4.7.5 4.7.6 4.7.7 accordin 4.8 SP 4.9 GE 4.9.1 4.9.1.1 4.9.1.2 4.9.2 4.9.3 4.9.4 4.9.5 4.9.6 4.10 CA 4.10.1 4.10.2 4.10.3 4.10.4 4.10.5 4.11 TC 4.11.1	Summary and discussion of repeated dose toxicity findings relevant for classification accordi 43 Comparison with criteria of repeated dose toxicity findings relevant for classification accord 43 Conclusions on classification and labelling of repeated dose toxicity findings relevant for cla g to DSD	ing to DSD ling to DSD ssification 43 43 44 44 44 44 44 44 45 45 46 46 46 46 46 46 46 46 46 46 47 47 47 47 47 47 47 48 48
4.7.5 4.7.6 4.7.7 accordin 4.8 SP 4.9 GE 4.9.1 4.9.1.1 4.9.1.2 4.9.2 4.9.3 4.9.4 4.9.5 4.9.6 4.10 CA 4.10.1 4.10.2 4.10.3 4.10.4 4.10.5 4.11 TC 4.11.1 4.11.1	Summary and discussion of repeated dose toxicity findings relevant for classification accordi 43 Comparison with criteria of repeated dose toxicity findings relevant for classification accord 43 Conclusions on classification and labelling of repeated dose toxicity findings relevant for cla g to DSD CIFIC TARGET ORGAN TOXICITY (CLP REGULATION) – REPEATED EXPOSURE (STOT RE) RM CELL MUTAGENICITY (MUTAGENICITY) Non-human information In vitro data	ing to DSD ling to DSD ssification 43 43 44 44 44 44 44 44 45 45 45 46 46 46 46 46 46 46 46 46 47 47 47 47 47 47 47 48 48 48 48
4.7.5 4.7.6 4.7.7 accordin 4.8 SP 4.9 GE 4.9.1 4.9.1.1 4.9.1.2 4.9.2 4.9.3 4.9.4 4.9.5 4.9.6 4.10 CA 4.10.1 4.10.2 4.10.3 4.10.4 4.10.5 4.11 TC 4.11.1 4.11.1	Summary and discussion of repeated dose toxicity findings relevant for classification accordi 43 Comparison with criteria of repeated dose toxicity findings relevant for classification accord 43 Conclusions on classification and labelling of repeated dose toxicity findings relevant for cla g to DSD	ing to DSD ling to DSD ssification 43 43 44 44 44 44 44 45 45 45 46 46 46 46 46 46 46 46 46 47 47 47 47 47 47 47 48 48 48 48 48
4.7.5 4.7.6 4.7.7 accordin 4.8 SP 4.9 GE 4.9.1 4.9.1.1 4.9.1.2 4.9.2 4.9.3 4.9.4 4.9.5 4.9.6 4.10 CA 4.10.1 4.10.2 4.10.3 4.10.4 4.10.5 4.11 TC 4.11.1 4.11.1 4.11.2	Summary and discussion of repeated dose toxicity findings relevant for classification accordi 43 Comparison with criteria of repeated dose toxicity findings relevant for classification accord 43 Conclusions on classification and labelling of repeated dose toxicity findings relevant for cla g to DSD	ing to DSD ling to DSD ssification 43 43 44 44 44 44 44 44 45 45 45 46 46 46 46 46 46 46 46 46 46 46 47 47 47 47 47 47 47 48 48 48 48 48 48 48
4.7.5 4.7.6 4.7.7 accordin 4.8 SP 4.9 GE 4.9.1 4.9.1.1 4.9.1.2 4.9.2 4.9.3 4.9.4 4.9.5 4.9.6 4.10 CA 4.10.1 4.10.2 4.10.3 4.10.4 4.10.5 4.11 TC 4.11.1 4.11.1 4.11.2 4.11.2 4.11.2	Summary and discussion of repeated dose toxicity findings relevant for classification accordi 43 Comparison with criteria of repeated dose toxicity findings relevant for classification accord 43 Conclusions on classification and labelling of repeated dose toxicity findings relevant for cla g to DSD. CIFIC TARGET ORGAN TOXICITY (CLP REGULATION) – REPEATED EXPOSURE (STOT RE) RM CELL MUTAGENICITY (MUTAGENICITY). Non-human information	ing to DSD ling to DSD ssification 43 43 44 44 44 44 44 44 44 44 45 45 46 46 46 46 46 46 46 46 46 46 46 47 47 47 47 47 47 47 47 47 49 49 49 49
4.7.5 4.7.6 4.7.7 accordin 4.8 SP 4.9 GE 4.9.1 4.9.1.1 4.9.1.2 4.9.2 4.9.3 4.9.4 4.9.5 4.9.6 4.10 CA 4.10.1 4.10.2 4.10.3 4.10.4 4.10.5 4.11 TC 4.11.1 4.11.1 4.11.2 4	Summary and discussion of repeated dose toxicity findings relevant for classification accordi 43 Comparison with criteria of repeated dose toxicity findings relevant for classification accord 43 Conclusions on classification and labelling of repeated dose toxicity findings relevant for cla g to DSD	ing to DSD ling to DSD ssification 43 43 44 44 44 44 44 44 44 44 44 45 45 46 46 46 46 46 46 46 46 46 46 46 47 47 47 47 47 47 47 47 48 48 48 48 48 49 49 49
4.7.5 4.7.6 4.7.7 accordin 4.8 SP 4.9 GE 4.9.1 4.9.1.1 4.9.1.2 4.9.2 4.9.3 4.9.4 4.9.5 4.9.6 4.10 CA 4.10.1 4.10.2 4.10.3 4.10.4 4.10.5 4.11 TC 4.11.1 4.11.2 4.11.2 4.11.2 4.11.2 4.11.3	Summary and discussion of repeated dose toxicity findings relevant for classification accordi 43 Comparison with criteria of repeated dose toxicity findings relevant for classification accord 43 Conclusions on classification and labelling of repeated dose toxicity findings relevant for cla g to DSD	ing to DSD ling to DSD ssification 43 43 44 44 44 44 44 44 44 44 44 44 45 45 46 46 46 46 46 46 46 46 46 46 47 47 47 47 47 47 47 47 47 47 49 49 49 49 49

<ul> <li>4.11.6 Conclusions on classification and labelling</li></ul>	
<ul> <li>4.12 OTHER EFFECTS.</li> <li>4.12.1 Non-human information</li></ul>	
<ul> <li>4.12.1 Non-human information</li></ul>	
<ul> <li>4.12.1.1 Neurotoxicity</li></ul>	
<ul> <li>4.12.1.2 Immunotoxicity</li></ul>	
<ul> <li>4.12.1.3 Specific investigations: other studies</li></ul>	
<ul> <li>4.12.2 Human information</li></ul>	
<ul> <li>4.12.3 Summary and discussion</li></ul>	
<ul> <li>4.12.4 Comparison with criteria</li> <li>4.12.5 Conclusions on classification and labelling</li> <li>5 ENVIRONMENTAL HAZARD ASSESSMENT</li> <li>5.1 DEGRADATION</li> <li>5.1.1 Stability</li> <li>5.1.2 Biodegradation</li> </ul>	
<ul> <li>4.12.5 Conclusions on classification and labelling</li> <li>5 ENVIRONMENTAL HAZARD ASSESSMENT</li></ul>	
5 ENVIRONMENTAL HAZARD ASSESSMENT 5.1 DEGRADATION 5.1.1 Stability 5.1.2 Biodegradation	
5.1       DEGRADATION         5.1.1       Stability         5.1.2       Biodegradation	51
5.1.1       Stability         5.1.2       Biodegradation	51
5.1.2 Biodegradation	
5.1.2.1 Biodegradation estimation	
5.1.2.2 Screening tests	
5.1.2.3 Simulation tests	53
5.1.3 Summary and discussion of degradation	
5.2 Environmental distribution	
5.2.1 Adsorption/Desorption	
5.2.2 Volatilisation	
5.2.3 Distribution modelling	
5.3 AQUATIC BIOACCUMULATION	55
5.3.1 Aquatic bioaccumulation	
5.3.1.1 Bioaccumulation estimation	55
5.3.1.2 Measured bioaccumulation data	55
5.3.2 Summary and discussion of aquatic bioaccumulation	
5.4 AQUATIC TOXICITY	56
CLASSIFICATION IS BASED ON THE KEY STUDIES (RESULTS AND REFERENCES HIGHLIGHTED BOLD	) 56
5.4.1 Fish	
5.4.1.1 Short-term toxicity to fish	
5.4.1.2 Long-term toxicity to fish	57
5.4.2 Aquatic invertebrates	
5.4.2.1 Short-term toxicity to aquatic invertebrates	57
5.4.2.2 Long-term toxicity to aquatic invertebrates	
5.4.3 Algae and aquatic plants	
5.4.4 Other aquatic organisms (including sediment)	
5.5 Comparison with criteria for environmental hazards (sections $5.1 - 5.4$ )	59
5.6 CONCLUSIONS ON CLASSIFICATION AND LABELLING FOR ENVIRONMENTAL HAZARDS (SI	ECTIONS 5.1 – 5.4)61
CLP:	61
6 OTHER INFORMATION	62
7 REFERENCES	63
8 ANNEXES	76

# Part A.

## **1 PROPOSAL FOR HARMONISED CLASSIFICATION AND LABELLING**

#### 1.1 Substance

#### Table 1:Substance identity

Substance name:	Decanoic acid
EC number:	206-376-4
CAS number:	334-48-5
Annex VI Index number:	n.a.
Degree of purity:	98.5%w/w
Impurities:	see confidential Annex

#### **1.2** Harmonised classification and labelling proposal

#### Table 2: The current Annex VI entry and the proposed harmonised classification

	CLP Regulation (including criteria according to 2 <sup>nd</sup> ATP of CLP)	Directive 67/548/EEC (Dangerous Substances Directive; DSD)
Current entry in Annex VI, CLP Regulation	Not currently in Annex VI, Table 3.1 of the CLP Regulation	Not currently in Annex VI, Table 3.2 of the CLP Regulation
Current proposal for consideration by RAC	Skin Irritation 2 – H315 Eye Damage 1 – H318 Aquatic Chronic 3 – H412	Xi; Irritating N; Dangerous for the environment R38 R41 R 51/53
<b>Resulting harmonised classification</b> (future entry in Annex VI, CLP	Skin Irritation 2 – H315	Xi; Irritating N: Dangerous for the

Regulation)	Eye Damage 1 – H318	environment
	Aquatic Chronic 3 – H412	R38
		R41
		R 51/53

Proposed harmonised classification and labelling based on CLP Regulation and/or DSD criteria

Table 3:	Proposed classification according to the CLP Regulation (including criteria
according to	2 <sup>nd</sup> ATP of CLP)

CLP Annex I ref	Hazard class	Proposed classification	Proposed SCLs and/or M- factors	Current classification <sup>1)</sup>	<b>Reason for no</b> classification <sup>2)</sup>
2.1.	Explosives	n.a.	n.a.	currently not classified	conclusive but not sufficient for classification
2.2.	Flammable gases	n.a.	n.a.	currently not classified	data lacking
2.3.	Flammable aerosols	n.a.	n.a.	currently not classified	data lacking
2.4.	Oxidising gases	n.a.	n.a.	currently not classified	data lacking
2.5.	Gases under pressure	n.a.	n.a.	currently not classified	data lacking
2.6.	Flammable liquids	n.a.	n.a.	currently not classified	data lacking
2.7.	Flammable solids	n.a.	n.a.	currently not classified	conclusive but not sufficient for classification
2.8.	Self-reactive substances and mixtures	n.a.	n.a.	currently not classified	conclusive but not sufficient for classification
2.9.	Pyrophoric liquids	n.a.	n.a.	currently not classified	data lacking
2.10.	Pyrophoric solids	n.a.	n.a.	currently not classified	data lacking
2.11.	Self-heating substances and mixtures	n.a.	n.a.	currently not classified	data lacking
2.12.	Substances and mixtures which in contact with water emit flammable gases	n.a.	n.a.	currently not classified	conclusive but not sufficient for classification
2.13.	Oxidising liquids	n.a.	n.a.	currently not classified	data lacking
2.14.	Oxidising solids	n.a.	n.a.	currently not classified	conclusive but not sufficient for classification
2.15.	Organic peroxides	n.a.	n.a.	currently not classified	conclusive but not sufficient for classification
2.16.	Substance and mixtures corrosive to metals	n.a.	n.a.	currently not classified	data lacking
3.1.	Acute toxicity - oral	n.a.	n.a.	currently not classified	conclusive but not sufficient for

					classification
	Acute toxicity - dermal	n.a.	n.a.	currently not classified	conclusive but not sufficient for classification
	Acute toxicity - inhalation	n.a.	n.a.	currently not classified	conclusive but not sufficient for classification
3.2.	Skin corrosion / irritation	Skin Irrit. 2 H315: Causes skin irritation.	n.a.	currently not classified	n.a.
3.3.	Serious eye damage / eye irritation	Eye Damage 1 H318: Causes serious eye damage.	n.a.	currently not classified	n.a.
3.4.	Respiratory sensitisation	n.a.	n.a.	currently not classified	data lacking
3.4.	Skin sensitisation	n.a.	n.a.	currently not classified	conclusive but not sufficient for classification
3.5.	Germ cell mutagenicity	n.a.	n.a.	currently not classified	conclusive but not sufficient for classification
3.6.	Carcinogenicity	n.a.	n.a.	currently not classified	conclusive but not sufficient for classification
3.7.	Reproductive toxicity	n.a.	n.a.	currently not classified	conclusive but not sufficient for classification
3.8.	Specific target organ toxicity –single exposure	n.a.	n.a.	currently not classified	conclusive but not sufficient for classification
3.9.	Specific target organ toxicity – repeated exposure	n.a.	n.a.	currently not classified	conclusive but not sufficient for classification
3.10.	Aspiration hazard	n.a.	n.a.	currently not classified	conclusive but not sufficient for classification
4.1.	Hazardous to the aquatic environment	Aquatic Chronic 3 H412: Harmful to aquatic life with long lasting effects.	n.a.	currently not classified	n.a.
5.1.	Hazardous to the ozone layer	n.a.	n.a.	currently not classified	data lacking

<sup>1)</sup> Including specific concentration limits (SCLs) and M-factors <sup>2)</sup> Data lacking, inconclusive, or conclusive but not sufficient for classification

#### Labelling: <u>Signal word:</u> Danger

<u>Hazard statements:</u>
H315: Causes skin irritation.
H318: Causes serious eye damage.
H412: Harmful to aquatic life with long lasting effects
<u>Precautionary statements:</u>
P264: Wash ... thoroughly after handling.
P273: Avoid release to the environment.
P280: Wear protective gloves/protective clothing/eye protection/face protection.
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P310: Immediately call a POISON CENTER or doctor/physician.
P302+P352: IF ON SKIN: Wash with plenty of soap and water.
P332+P313: If skin irritation occurs: Get medical advice/attention.
P362: Take off contaminated clothing and wash before reuse.
P501: Dispose of contents/container to ...

#### Proposed notes assigned to an entry:

None

Hazardous property	Proposed classification	Proposed SCLs	Current classification <sup>1)</sup>	<b>Reason for no</b> classification <sup>2)</sup>
Explosiveness	n.a.	n.a.	currently not classified	conclusive but not sufficient for classification
Oxidising properties	n.a.	n.a.	currently not classified	conclusive but not sufficient for classification
Flammability	n.a.	n.a.	currently not classified	conclusive but not sufficient for classification
Other physico-chemical properties	n.a.	n.a.	currently not classified	
Thermal stability	n.a.	n.a.	currently not classified	conclusive but not sufficient for classification
Acute toxicity	n.a.	n.a.	currently not classified	conclusive but not sufficient for classification
Acute toxicity – irreversible damage after single exposure	n.a.	n.a.	currently not classified	conclusive but not sufficient for classification
Repeated dose toxicity	n.a.	n.a.	currently not classified	conclusive but not sufficient for classification
Irritation / Corrosion	Xi; R38 Irritant; Irritating to skin. Xi; R41 Irritant; Risk of serious damage to eyes.	n.a.	currently not classified	n.a.
Sensitisation	n.a.	n.a.	currently not classified	conclusive but not sufficient for classification
Carcinogenicity	n.a.	n.a.	currently not classified	conclusive but not sufficient for classification
Mutagenicity – Genetic toxicity	n.a.	n.a.	currently not classified	conclusive but not sufficient for classification
Toxicity to reproduction – fertility	n.a.	n.a.	currently not classified	conclusive but not sufficient for classification
Toxicity to reproduction – development	n.a.	n.a.	currently not classified	conclusive but not sufficient for classification
Toxicity to reproduction – breastfed babies. Effects on or via lactation	n.a.	n.a.	currently not classified	conclusive but not sufficient for classification
Environment	N; R51/53 Dangerous for the environment; Toxic to aquatic organisms, may cause long- term adverse effects in the aquatic environment.	n.a.	currently not classified	n.a.

Proposed classification according to DSD Table 4:

<sup>1)</sup> Including SCLs
 <sup>2)</sup> Data lacking, inconclusive, or conclusive but not sufficient for classification

Labelling:

Indication of danger:

Xi – Irritant

N - Dangerous for the environment

<u>R-phrases:</u> R38 - Irritating to skin R41 - Risk of serious damage to eyes R51/53 - Toxic to aquatic organisms, may cause long-term adverse effects in the aquatic environment.

<u>S-phrases:</u> S26 - in case of contact with eyes, rinse immediately with plenty of water and seek medical advice S36/37/39 - wear suitable protective clothing, gloves and eye/face protection S61 - Avoid release to the environment. refer to special instructions/safety data sheets.

#### **2** BACKGROUND TO THE CLH PROPOSAL

#### 2.1 History of the previous classification and labelling

There is no current classification according to Annex I of Council Directive 67/548/EEC.

There is also no current classification according to Table 3.1 of Annex VI of Regulation (EC) No 1272/2008.

#### 2.2 Short summary of the scientific justification for the CLH proposal

#### Human Toxicology:

Weight of evidence evaluation supporting skin irritation and risk for serious eye damage:

The in vitro transcutaneous electrical resistance (TER) data for decanoic acid from York 1996 indicate that the substance is not corrosive on the human skin in vitro. An in vitro EpiDerm test with decanoic acid indicated that the substance is at least skin irritating (Jirova et al. 2008). Human patch test data also support "at least skin irritation". Old literature data also support severe skin irritation. The standard in vivo data for nonanoic acid appear borderline with regard to skin irritation category 1 or 2. In contrast Whittle 1994 provided for octanoic acid a rat TER in vitro skin corrosivity test indicative for skin corrosion. This test is not directly comparable with the York 1996 in vitro TER data for decanoic acid (indicating non-corrosion), since the latter was carried out with human skin samples and a slightly different prediction model. However we consider that with increasing chain length the irritant property of the carbonic acids is reduced. Consequently the in vitro TER data for decanoic acid are considered as decisive and therefore we propose on the basis of a total weight of evidence evaluation to classify decanoic acid not as skin corrosive but as skin irritant (category 2, H315).

For the estimation of eye irritation hazard no OECD standard studies are available for Octanoic acid or for Decanoic acid. A severe skin irritation would, according to OECD guideline 405, exclude further eye irritation testing with animals and result in classification as severely eye damaging. Furthermore two publications were identified, attributing score 9 from 10 for corneal necrosis (Smith et al. 1962, no information on reversibility) or indicating corneal opacity and no reversibility up to 72 hours (Briggs et al 1976) for Decanoic acid. These references summarize the same results for Octanoic acid. According to the actual GHS criteria category 1 would result from a corneal score of 3 (from maximum 4) in at least 2 of 3 tested animals or non reversibility of corneal effects in at least one animal. Considering the observation of a corneal score of 9 (from maximum 10) and no observation of reversibility Decanoic acid needs to be classified for risk of severe damage to eye (R41) according to DSD criteria or eye irritant category I (H318) according to GHS.

#### Environment:

Acute aquatic toxicity:  $L(E)C_{50}$  values between 1 - 100 mg/L; lowest acute value  $E_rC_{50}$  (algae) =2 mg/L; Chronic Aquatic toxicity: only one NOE<sub>r</sub>C value for algae available =0.57 mg/L (geometric mean); Fate & behaviour: rapidly biodegradable; log  $P_{ow}$ =4.09; BCF estimated for fish =597.72;

Proposed C&L (according to the data summarised above):

#### CLP:

- No classification with Aquatic Acute 1, since all available acute toxicity values >1 mg/L.
- Classification with Aquatic Chronic 3 on the basis of the only available chronic NOE<sub>r</sub>C value from algae with 0.57 mg/L in combination with rapid biodegradability and also on basis of L(E)C<sub>50</sub> values from fish and crustacea in the range of 10-100 mg/L in combination with ready biodegradability and a log P<sub>ow</sub> of 4.09. The calculated BCF value was not taken into account for classification, since only experimentally derived BCF values are considered relevant for classification.

#### DSD:

- All available L(E)C<sub>50</sub> values are between 1 and 100 mg/L. The lowest  $E_rC_{50}$  from algae with 2 mg/L in combination with a log P<sub>ow</sub> value of 4.09 leads to a classification with N; R51/53 and S61. The calculated BCF value was not taken into account for classification, since only experimentally derived BCF values are considered relevant for classification.

#### 2.3 Current harmonised classification and labelling

#### 2.3.1 Current classification and labelling in Annex VI, Table 3.1 in the CLP Regulation

No current classification and labelling.

#### 2.3.2 Current classification and labelling in Annex VI, Table 3.2 in the CLP Regulation

No current classification and labelling.

#### 2.4 Current self-classification and labelling

#### 2.4.1 Current self-classification and labelling based on the CLP Regulation criteria

No current classification and labelling.

Classifiesting

#### 2.4.2 Current self-classification and labelling based on DSD criteria

Classification	
Class of danger	Xi (irritant)
R phrases	R36/38

S phrases

S2, 24/25, 36/37/39

#### **3** JUSTIFICATION THAT ACTION IS NEEDED AT COMMUNITY LEVEL

Biocides: No need for justification.

Also conclusion for non-classification for the various endpoints is of utmost importance for European harmonisation. RMS proposals for classification and non-classification were not discussed in detail within the European Biocides Technical Meetings.

# Part B.

# SCIENTIFIC EVALUATION OF THE DATA

#### **1 IDENTITY OF THE SUBSTANCE**

1.1 <u>Name and other identifiers of the substance</u>

#### Table 5:Substance identity

EC number:	206-376-4
EC name:	decanoic acid
CAS number (EC inventory):	334-48-5
CAS number:	334-48-5
CAS name:	Decanoic acid
IUPAC name:	Decanoic acid
CLP Annex VI Index number:	not applicable
Molecular formula:	$C_{10}H_{20}O_2$
Molecular weight range:	172.27 g/mol

#### Structural formula:



#### 1.2 <u>Composition of the substance</u>

See confidential Annex. (concerns Table 6-8)

Current Annex VI entry: No current Annex VI entry.

#### **1.2.1** Composition of test material

See confidential Annex.

#### 1.3 <u>Physico-chemical properties</u>

#### Table 9: Summary of physico - chemical properties

Property	Purity/Specification	Results	Reference
Melting point	100%	29.8 -31.6+0.1 °C	Doc. III-A 3; Study A3/01D
Boiling point	100%	146.8-147.8 ±0.5°C at 10 mm Hg Normal pressure Decanoic acid starts to decompose at 264.5 °C	Doc. III-A 3; Study A3/01D

Property	Purity/Specification	Results	Reference
Density	99.5%	density $\rho = 0.674$ kg/L (20°C) (This is a density and not a relative density).	Doc. III-A 3; Study A3/03rev09
Vapour pressure	100%	2.17 x 10-4 Pa (25°C) 2.096 x 10-4 Pa (20°C)	Doc. III-A 3; Study A3/01D
Henry´s Law Constant	n.a.	0.472 Pa x m <sup>3</sup> x mol <sup>-1</sup> (calculated)	Doc. III-A 3; Study A3/04
Physical state	99.6%	Solid	Doc. III-A 3; Study A3/05
Colour	99.6%	White crystal	Doc. III-A 3; Study A3/05
Odour	99.6%	Rancid	Doc. III-A 3; Study A3/05
Absorption spectra: UV/VIS	100%	The test substance shows an absorption maximum at 208.4 nm and an minimum at 201.9 nm in methanol, a maximum at 208.0 nm and an minimum at 201.9 nm In 1N Hcl/methanol (90/10 v/v/) abd no absorption maximum or minimum in 1 N NaOH/methanol (10/90 v/v/)	Doc. III-A 3; Study A3/01D
Absorption spectra: IR	100%	IR, spectra in agreement with proposed structure	Doc. III-A 3; Study A3/01D
Absorption spectra: NMR	100%	<sup>1</sup> H, <sup>13</sup> C-NMR spectra in agreement with proposed structure	Doc. III-A 3; Study A3/01D
Absorption spectra: MS	100%	mass spectra in agreement with proposed structure	Doc. III-A 3; Study A3/01D
Water solubility	99%	Water: 43 mg/L;(20°C) pH 4: 31 mg/L;(20°C) pH 7: 1843 mg/L;(20°C) pH 9: 2882 mg/L;(20°C) OECD 105; EU A.6 Solubility at 35°C and 50°C not measurable	Doc. III-A 3; Study A3/16
Dissociation constant	n.a.	The reported dissociation constant (pK. value at 25°C) of n-Octanoic acid is 4.89 (Handbook of Chemistry and Physics, 79' edition 1998- 1999, pp. 8-46/56). The dissociation constant (pK value at 25'C) of n-Decanoic acid in water is extrapolated from known pK values of other alkyl homologues and is expected to be in the range from 4.89 to 5.03.	Doc. III-A 3; Study A3/02

Property	<b>Purity/Specification</b>	Results	Reference
Solubility in organic solvents, including the effects of temperature on stability	99.6%	Solubility in organic solvents of Decanoic acid is >1kg/L Hexane at 22°C and > 1kg/L Ethanol at 22°C	Doc. III-A 3; Study A3/17
Stability in organic solvents used in b.p. and identity of relevant breakdown products	99.6 ±0,5 %	Expert Statement; Not relevant. The active substance as manufactured does not include any organic solvent	Doc. III-A 3.8; Expert Statement
Partition coefficient n- octanol/water	n.a.	Calculated with KOWWIN: Log Kow = 4.02 Reference in the Program KOWWIN Log Kow = 4.09 For the undissociate acid	Doc. III-A 3; Study A3/04
Thermal stability identity of relevant breakdown products	n.a.	Decanoic acid is stable up to the boiling point. Expert Statement: Decanoic acid will burn after ignition and produce water, carbondioxid_carbonmonoxid and	Doc. III-A 3; Study A3/07_rev Doc. III-A 3; Study A 3/08
		unidentified hydrocarbons.	
Flammability, including autoflammability and identity of combustion products	n.a.	The heat of combustion is -6107.7 kJ/mol (Kirk-Othmer Encyclopedia of Chemical Technology, 4th ed. Volumes 1: 1991), therefore auto flammability is not expected	Doc. III-A 3; Study A3/08
Flash point	99.6 % ± 0.5%	Result: 178 °C	Doc. III-A 3; Study A3.18 Doc. III-A 3; Study A3/18a
Property	Purity/Specification	Results	Reference
Surface tension	n.a.	Octanoic acid is surface active. Due to the similar molecular structure, it is expected that Decanoic acid may also be surface active.	A 3/10rev09 from the Octanoic acid CAR (see also Company Statement "Agreement regarding the transfer of test reports between Octanoic and Decanoic acid")
Viscosity	99%	result: 6.5 mPa.s (45 °C)	Doc. III-A 3; Study A3/03b
Explosive properties	n.a.	Decanoic Acid does not contain structural elements such as peroxide, nitro-group known to cause explosions.	Doc. III-A 3; Study A3/12

Property	Purity/Specification	Results	Reference
Oxidizing properties	n.a.	Decanoic acid is a solid. It is no strong acid, which may oxidize other materials in a situation as described in the EU method A.14. It is unlikely that Decanoic acid shows oxidizing properties under the condition of the test.	Doc. III-A 3; Study A3/13
Reactivity towards container material	n.a.	Uncoated metal containers should be avoided. Plastic containers made of polyethylene or polypropylene and certified for use with acid are recommended	Doc. III-A 3; Study A3/14 Study A3/15
Granulometry		No data requirement in the biocidal dossier	

## 2 MANUFACTURE AND USES

#### 2.1 Manufacture

Biocides: Does not need to be specified for the CLH proposal.

#### 2.2 Identified uses

Insecticide, product type 18

Repellent, product type 19

Food and feed area disinfectant, product type 4

### **3** CLASSIFICATION FOR PHYSICO-CHEMICAL PROPERTIES

Property	<b>Purity/Specification</b>	Results	Reference
Thermal stability identity of relevant breakdown products	n.a.	Decanoic acid is stable up to the boiling point. Expert Statement: Decanoic acid will	Doc. III-A 3; Study A3/07_rev Doc. III-A 3;
		burn after ignition and produce water, carbondioxid, carbonmonoxid and unidentified hydrocarbons.	Study A 3/08
Flammability, including autoflammability and identity of combustion products	n.a.	The heat of combustion is -6107.7 kJ/mol (Kirk-Othmer Encyclopedia of Chemical Technology, 4th ed. Volumes 1: 1991), therefore auto flammability is not expected	Doc. III-A 3; Study A3/08
Flash point	$99.6 \ \% \pm 0.5\%$	Result: 178 °C	Doc. III-A 3; Study A3.18 Doc. III-A 3;
			Study A3/18a
Explosive properties	n.a.	Decanoic Acid does not contain structural elements such as peroxide, nitro-group known to cause explosions.	Doc. III-A 3; Study A3/12
Oxidizing properties	n.a.	Decanoic acid is a solid. It is no strong acid, which may oxidize other materials in a situation as described in the EU method A.14. It is unlikely that Decanoic acid shows oxidizing properties under the condition of the test.	Doc. III-A 3; Study A3/13
Reactivity towards container material	n.a.	Uncoated metal containers should be avoided. Plastic containers made of polyethylene or polypropylene and certified for use with acid are recommended	Doc. III-A 3; Study A3/14 Study A3/15

 Table 10:
 Summary table for relevant physico-chemical studies

#### 3.1 All hazard classes

#### 3.1.1 Summary and discussion of all hazard classes

No classification is proposed based on available data.

#### 3.1.2 Comparison with criteria

No classification is proposed based on available data.

#### 3.1.3 Conclusions on classification and labelling

No classification is proposed based on available data.

#### 4 HUMAN HEALTH HAZARD ASSESSMENT

#### 4.1 Toxicokinetics (absorption, metabolism, distribution and elimination)

#### Absorption

#### Oral

After oral ingestion of medium chain triglycerides (MCTs) they are hydrolyzed by lingual lipase in the stomach and then rapidly and efficiently by pancreatic lipase within the intestinal lumen (see e.g. Traul et al. 2000, Ref A 6.11). Free medium-chain fatty acids may be expected to be quickly and completely absorbed from the intestine (see e.g. Opdyke D.L.J. 1979). For oral application of Octanoic acid or MCTs 100% absorption can therefore be assumed.

#### Dermal

No studies on skin absorption are available. Undissociated Octanoic acid with a log  $P_{OW}$  of 3.03 as well as undissociated Decanoic acid with a log Pow of 4.09 is expected to easily penetrate and cross cell membranes. As it is found with absorption from the gut, it is appropriate to assume that the permeation through skin is easy. Also the skin irritating effects of the C8 and C10 fatty acids would support dermal absorption, on the other hand the low water solubility would limit dermal absorption. However after skin contact, the formation of a reservoir of the active substance in the stratum corneum and desquamation of the stratum corneum in time will result in less than 100% systemic availability.

Nevertheless in the absence of a dermal uptake study for the purpose of risk assessment 100% absorption of C8 and C10 fatty acids through the skin will be assumed.

#### Metabolism and distribution

After absorption from the gut C8 and C10 fatty acids are extensively metabolised in the liver. Only a minor fraction bypasses the liver and becomes distributed to peripheral tissues via the general circulation. C8 and C10 fatty acids are catabolised predominantly in the liver to C2 fragments, which are further converted to CO2 or used to synthesize longer-chain fatty acids.

C8 and C10 fatty acids not absorbed from the gut, but entering the body by dermal absorption can be expected to become absorbed into the blood stream and transported to the liver. A general overview of the digestion, absorption and transport of fats is shown in Figure 1 while the hepatic metabolism of fatty acids is shown in Figure 2.



FIG. 2. Hepatic metabolism of fatty acids. TG, triacylglycerols, PL, phospholipids: CE, esterified cholesterol; CPT, carnitine palmityl transferase.

Figure 2 from Bach A.C. and Babayan V.K. (1982)

The metabolites formed in the liver from C8 and C10 fatty acids are also substances normally present and part of the physiological system.

For a more detailed summary of the absorption and metabolism of medium chain fatty acids also the CAR of Nonanoic acid may be consulted.

Decanoic acid and Octanoic acid are naturally present in many types of food in its free form or as triglyceride (see Gubler 2006, Ref A 6/05). Uptake as natural food source from cheese or coconut oil may be estimated to be significantly above 10 mg/ person day (=estimation from average Swiss cheese consumption; 178 mg Decanoic acid and 200 mg Octanoic acid per person and day = estimation from average coconut oil consumption; up to 2000 mg Decanoic acid and 750 mg Octanoic acid per person and day = estimation from 100 g sheep cheese; see Document III-A 6.5.1 and 2). The latter two estimates are in the range of the proposed AEL (Acceptable Exposure Level).

Free fatty acid consumption as food flavouring agent was estimated by JECFA (Joint Expert Committee on food additives, codex alimentarius, FAO/WHO) to be for Decanoic acid 0.980 mg/day (USA) or 1.4 mg/day (Europe) and for Octanoic acid 0.65 mg/day (USA) or 3.8 mg/day (Europe) (WHO 1998 Ref. A6/07, WHO 2005 Ref A6/13)

The daily human uptake of total fatty acids as food contents (mainly as fat) may be estimated e.g. based on the publications of Henderson et al 2003 and Ruston et al.. These publications contain details on average fatty acid consumption (Henderson et al 2003) and mean actual male and female body weight data (Ruston et al . 2006). In adults aged 19 to 64 years in the UK, the mean ( $\pm$  s) daily intake of total fat for men is 86.5 ( $\pm$  28.2) g, which equates to a mean of 79.7 g total fatty acids and for women the daily intake of total fat is significantly lower at 61.4 ( $\pm$ 21.7) g, which equates to a mean of 56.7 g total fatty acids (Henderson et al . 2003). Mean ( $\pm$  s) body mass is 84 ( $\pm$ 15) kg for men and 69 ( $\pm$ 15) kg for women (Ruston et al . 2006). These figures equate to 949 mg of fatty acids per kg body weight per day for men, and 821 mg fatty acids per kg body weight per day for women.

This estimation may further support the high AEL for the free fatty acids Decanoic acid and Octanoic acid (> 10 mg/kg bw day).

#### 4.1.1 Non-human information

See chapter 4.1.

#### 4.1.2 Human information

See chapter 4.1.

#### 4.1.3 Summary and discussion on toxicokinetics

See chapter 4.1.

#### 4.2 Acute toxicity

#### 4.2.1 Non-human information

#### 4.2.1.1 Acute toxicity: oral

Table 11a Summary	of octanoic acid ac	cute toxicity for Octa	noic acid and Decanoic acid	
2		2		

Route	Method Guideline	Species Strain Sex no/group	Dose levels duration of exposure	Substance tested	Value LD <sub>50</sub> /LC <sub>50</sub>	Remarks	Reference
Oral	Similar to OECD 401	Rat Wistar, 5 rats/sex	Limit test 5 mg/kg bw	C8 fatty acid	> 5 mg/kg bw		Kästner 1981 Doc III-A 1.1
Oral	Similar to OECD 401 non GLP	Rat, Carworth- Wistar, 5 rats/group	not reported	C8 fatty acid C10 fatty acid	1300 mg/kg bw (~ 1.41 ml/kg bw) 3800 g/kg bw (3,73 ml/kg bw)		Smyth et al. 1962;
Oral	Not reported; non GLP	rat	Not reported	C10 fatty acid	4 entries from > 10 to > 10000 mg/kg bw		IUCLID 2000 (studies from 1975 to 1979 or date not given

#### 4.2.1.2 Acute toxicity: inhalation

Inhalation	Not reported	Rat, no information	No information available for dose	C9 fatty acid	$LC_{50}$ (4 h) >5.3 mg/L for		Copping L.G. 1998
------------	-----------------	------------------------	-----------------------------------	------------------	----------------------------------	--	----------------------

		available for strain, sex and number of animals used	levels used, 4 h duration of exposure		Nonanoic acid		(Bio- pesticide Manual) Doc. III-A 6.1.3/3 nona
Inhalation	Not reported	No information available for species, strain, sex and number of animals used	No information available for dose levels used,	C10 fatty acid C9 and C10 fatty acids: 60% formulation and C9 fatty acids: 80% formulation	$\begin{array}{l} LC_{50} \ (2 \ h) \\ > 4.1 \ mg/L \\ LC_{50} \ (4 \ h) \\ > 5.53 \ mg/L \\ \end{array}$ and $\begin{array}{l} LC_{50} \ (4 \ h) \\ > 5.9 \ mg/L \end{array}$		Anonymous (Safer Inc), date not stated Doc. III-A 6.1.3/4
Inhalation	Similar to OECD 403 non GLP	Rat, albino, 6 rats/group	Approximately saturated vapour ("concentrated vapour", no analytical confirmation); 4 hours (C8) or 8hours (C10) whole body exposure	C8 fatty acid C10 fatty acid	Approximately saturated vapour	No mortality	Smyth et al. 1962
Inhalation	Not reported; non GLP	No information	Saturated vapour; 8 hours	C10 fatty acid	Saturated vapour	No mortality	IUCLID 2000 (study from 1979)

Within the draft assessment report for fatty acids (C7-C20) prepared by RMS Ireland in the context of 91/414/EEC reference is also given to secondary, non-GLP, though consistent literature (HERA 2002, Guest 1982) indicating that neither concentrated Octanoic acid nor Nonanoic acid nor Decanoic acid did cause mortality with 4 to 8 hours of inhalation exposure. The RMS-AT did not independently assess these references since the available information seems sufficient also without these references.

#### 4.2.1.3 Acute toxicity: dermal

See

Dermal	OECD 402; EU B.3 GLP study from 2006	Rat, HanRcc:WIST (SPF) rats 5m+5f/dose group	2000 mg/kg bw (diluted ~25% in PEG) 24 hours	C10 fatty acid	> 2000 mg/kg	Reversible skin irritation in all animals; on day 2: moderate sedation (4m, 3f), deep respiration (3m, 2f), hunched posture (3m, 1f)	Talvioja K. 2006; Doc III-A 6.1.2,
Dermal	Similar to OECD 402	Rabbit, albino New Zealand,	not reported	C8 fatty acid	640 mg/kg bw		Smyth et al. 1962

non GLP	4 rats/group		(~0.71	
	r rate, group		ml/kg	
			bw)	

#### 4.2.1.4 Acute toxicity: other information

Additional information is available from acute toxicity studies for Nonanoic acid (data owner W. Neudorff GmbH KG) in the respective CLH Dossier and Biocides CAR. The results are consistent with those reported for Octanoic acid and Decanoic acid.

#### 4.2.2 Human information

Not available.

#### 4.2.3 Summary and discussion of acute toxicity

The acute toxicity data taken into consideration are summarised in the table 11 above. Most of the tests are older and not GLP approved. However the absence of adverse systemic effects is in line with the knowledge of its endogenous metababolism and the results of the available repeated dose studies. The results of the acute toxicity tests are consistent with each other. Furthermore WHO/ IPCS 1998 summarizes acute oral toxicity LD50 values for a series of carbonic acids including Octanoic and Decanoic acid, which are all above 1000 mg/kg bw. No classifications for acute oral, dermal or inhalation toxicity are required according to European Regulation 1272/2008/EC table 3.1 and 3.2. Adverse local effects are to be expected from the potential of severe irritation.

#### 4.2.4 Comparison with criteria

The acute oral toxicity studies indicate an LD50 above 2000 mg/kg bw, which is above the LD50 range that may lead to classification in category 4 (300 to 2000 mg/kg bw) or DSD category 3 (200 to 2000 mg/kg bw).

The acute inhalation toxicity studies indicate an LC50 above 5 mg/L, which is above the LD50 range that may lead to classification in category 4 (dust, mist 1 to 5 mg/L) or DSD category 3 (1 to 5 mg/L).

The acute dermal toxicity studies indicate an LD50 above 2000 mg/kg bw, which is above the LD50 range that may lead to classification in category 4 (1000 to 2000 mg/kg bw) or DSD category 3 (400 to 2000 mg/kg bw).

#### 4.2.5 Conclusions on classification and labelling

No classification is required.

#### 4.3 Specific target organ toxicity – single exposure (STOT SE)

No classification is required.

#### 4.4 Irritation

#### 4.4.1 Skin irritation

No specific guideline studies are available for Octanoic or Decanoic acid. However sufficient publications are available to assess the irritation potential by a total weight of evidence approach.

#### 4.4.1.1 Human information

The publication from York et al 1996 reports that Decanoic acid showed non-corrosive in the ex vivo human skin based Transcutaneous Electrical Resistance Test. No full study report is available, but the brief method description is in line with the respective OECD guideline 430.

Jirova et al. 2008 reports new in vitro skin irritation data with the EpiDerm model with application times of 15 minutes and with 60 minutes. This new EpiDerm protocol (Spielmann et al. 2007) is designed and validated (ESAC 2007, adopted in EU, OECD process ongoing) to distinguish irritation from non-irritation. It differs from the EpiDerm protocol referenced by the OECD guideline 431 that differentiates corrosive from non-corrosive effects with regard to application time, recovery period and prediction model. Consequently the published EpiDerm results (Jirova et al 2008) support that Nonanoic acid and Decanoic acid are skin irritation (but do not inform weather these medium chain fatty acids might be corrosive).

Several human patch tests are available with the structurally related Decanoic and Octanoic acid, they meet the criteria of the Helsinky Declaration from 1964 and further details on the ethical and scientific acceptability are discussed in Robinson et al. 2001. Within a human patch test (see Robinson et al 1999) 72 human volunteers were exposed to 0.2 ml of Octanoic acid and 0.2 g of Decanoic acid in 0.2 ml distilled water, each to different skin areas. The patches were applied to the arms subsequently with increasing duration of 0.5, 1, 2, 3 and 4 hours. As soon as an individual participant showed at least mild, unequivocal erythema he was not further exposed for increasing duration already after up to 1 hour of exposure and 84 to 96% of the participants showed at least mild irritation already after up to 1 hour of exposure and 84 to 96% of the participants showed at least mild irritation after up to 4 hours of application. For Octanoic acid 10 from 69 individuals (ca. 15%) showed moderate skin reactions already at 3 hours, with these 10 participants no longer exposure was tested. For Decanoic acid 1 from 70 individuals showed moderate skin reactions and another one showed strong skin reactions, each after 2 hours. From an earlier publication (York et al. 1996) it also appears that within the human patch test Decanoic acid produced strong responses in some individuals already after 2 hours, but no further details are provided.

In addition Jirova et al. 2008 reports also a new human patch test that showed reversible irritation only after 4 hours of exposure, with 19 from 29 volunteers for Nonanoic acid and with 28 from 29 volunteers for melted Decanoic acid. (The fact that irritation was observed only after 4 hours and not after 0.25, 0.5, 1,2 or 3 hours of exposure is not explicit in the publication but personally communicated upon request of the RMS).

In addition, when Wahlberg 1983 applied 0.1 ml neat Nonanoic acid repeatedly for 15 days to his volar forearm he also did not report any corrosion.

Willis et al. 1988a reports the application of 40, 60, 70 and 80% Nonanoic acid to 48 hours to a total of 70 human volunteers with the aim to determine the optimum concentration of a number of irritants for use within clinical studies. For 26 volunteers at the concentration of 80% no corrosion but up to moderate skin reactions defined as erythema with oedema and papules were reported For similar clinical objectives Wahlberg et al. 1980 presented test results from the application of 5, 10, 20, 40% Nonanoic acid for 48 hours to healthy volunteers and dermatitis patients. 12 of the dermatitis patients received also 100% Nonanoic acid: With increasing concentration an increasing proportion of participants showed skin irritation, but no skin corrosion was reported for all concentrations. These latter 2 publications do not explicitly state the ethical standards that were applied; therefore this information is only reported for reasons of completeness.

#### 4.4.1.2 Non-human information

Further indications for the evaluation with regard to corrosion could be derived from the Toxtree QSAR tool provided by the ECB. It would result as borderline proposal "Irritating or corrosive to skin".

The acute dermal toxicity test with Decanoic acid was carried out with a 25% solution in PEG for 24 hours on rats. All rats showed signs of skin irritation which were reversible within 15 days.

Following the total weight of evidence approach also the study results from the skin irritation study with Nonanoic acid has to be quoted as additional information. It shows borderline results between skin irritation and skin corrosion (see CAR Nonanoic acid on CIRCA from 2008-10-22): The potential of Nonanoic acid to irritate skin was tested in male New Zealand rabbits. The animals were exposed for 4 hours to 0.5 mL of the undiluted tech. a.i.. Observations were made 1, 24, 48 and 72 hours and 7 and/or 14 days after exposure. No mortality and no symptoms of systematic toxicity were observed. Exposure to Nonanoic acid resulted in severe erythema and (very) slight oedema in the treated skin-areas of the rabbits, which had resolved within 15 days after exposure. Oedema could not be scored on days 3, 4 and/or 8 due to fissuring, scab formation and/or brown discolouration of the treated skin. Brown discolouration (sign of necrosis) of the treated skin was observed among all animals between days 1 and 8. Scabs, eschar formation and/or fissuring of the skin were noted on days 3, 4 and/or 8 among the animals. In addition a bald skin and scaliness were observed at the end of the observation period, at day 14, in all 3 animals.

Though no scars were reported the overall skin irritation effects need to be considered as severe and with regard to bald skin and scaliness did not resolve within 15 days after exposure. According to GHS corrosive reactions are typified by ulcers, bleeding, bloody scabs, and by the end of observation at 14 days, by discolouration due to blanching of the skin, complete areas of alopecia, and scars. Histopathology should be considered to evaluate questionable lesions. From these descriptors only "complete areas of alopecia" seem evident, which could –considering also the severe effects observed at the earlier time points- support classification as corrosive/category 1 according to GHS. The DSD criteria for classification are not that explicit. Nevertheless within the 19th ATP Nonanoic acid was classified as corrosive. However this was in 1993, the respective data basis is not clear and not available and the actual study is from 2001. Furthermore EPA (2003) classified Nonanoic acid as Toxicity category II for irritation that would be in line with classification as irritant/category 2 according to GHS or irritant according to the EU criteria. Neither Octanoic acid are actually classified in the EU.

Also the acute dermal toxicity test of Nonanoic acid as 22% solution in PEG for 24 hours led to some clinical signs and in 2 from 10 animals to severe irritation effects. However if we would calculate a medium score for erythema and scaling/scabs or swelling for 24, 48 and 72 hours (according to OECD scores) it would remain below 2 (see CAR Nonanoic acid on CIRCA from 2008-10-22, the study is data protected)

#### 4.4.1.3 Summary and discussion of skin irritation

The in vitro transcutaneous electrical resistance (TER) data for decanoic acid from York 1996 indicate that the substance is not corrosive on the human skin. An in vitro EpiDerm test with decanoic acid indicated that the substance is at least skin irritating (Jirova et al. 2008). Human patch test data also support "at least skin irritation". Old literature data also support severe skin irritation. The standard in vivo data for nonanoic acid appear borderline with regard to skin irritation category 1 or 2. In contrast Whittle 1994 provided for octanoic acid a rat TER in vitro skin corrosivity test indicative for skin corrosion. This test is not directly comparable with the York 1996 in vitro TER data for decanoic acid (indicating non-corrosion), since the latter was carried out with human skin samples and a slightly different prediction model. However we consider that with increasing chain length the irritant property of the carbonic acids is reduced. Consequently the in vitro TER data for decanoic acid are considered as decisive and therefore we propose on the basis of a total weight of evidence evaluation to classify decanoic acid not as skin corrosive but as skin irritant (category 2, H315).

Species, No of animals	Method	Conc.	Dose	Exposure time	Substance tested	Result	Reversibility yes/no	Conclusion from RMS	Reference
Human skin ex vivo	Transcutaneous Elektrical Resistance Test (TER); OECD guideline 430	100%		24 h	C10 fatty acid	$29.9 \pm 5.4 \text{ k}\Omega/\text{disc}$ (a value of $\leq 11$ k $\Omega/\text{disc}$ indicates that a substance could produce a corrosive effect on human skin in vivo)	n.a.	Not- corrosive to skin	York et al. 1996
EpiDerm (reconstituted human epidermis model)	In vitro skin irritation test (Spielmann et al 2007);	100%		15 minutes and 60 minutes	C9 and melted C10 fatty acid	irritant Prediction model: Tissue viability <50% or >50% and IL1α release 3x increased.	n.a.	At least irritating to skin	Jirova et al. 2008
Human volunteers	Human patch test	100%	200ml/ chamber	4h	melted C10 fatty acid C9 fatty acid	irritant with 18/29 volunteers irritant with 19/29 volunteers	Yes	irritating to skin	Jirova et al. 2008
Human, 72 volunteers	Human patch test Patches applied with graded duration of exposure. Assessment after 24/48/72h	100%	200 mg/chamber	≤4 graded: 0.5, 1, 2, 3, 4	C10 fatty acid C8 fatty acid	% participants showing at least mild irritation: 50 to 56% after 1 hour 78 to 82% after up to 2 hours 90 to 94 after up to 3 hours 92 to 97% after up to 4 hours	Yes	At least mildly irritating to skin	Robinson et al. 1999 Doc-III A6.1.4.s/02

Table 12a: Summary of skin irritation data for Octanoic, Nonanoic and Decanoic acid (public available or data protected and property of applicant)

						14 to 38% after 1 hour 50 to 62% after up to 2 hours 81 to 84% after up to 3 hours 85 to 89% after up to 4 hours			
Human volunteer (author of publication)	Human patch test	100%, 60%, 40%, 20%, 10%, 5% in propanol	0.1 ml	repeated for 15 days	C9 fatty acid	Increased skin thickness for concentrations ≥40%		Irritating to skin	Wahlberg 1983
Human 8 volunteers	Human 24 hours exposure, measurement 20 minutes after patch removal	2.5%, 5%, 10%, 20% in propanol		24 hours	C9 fatty acid	2.5% or 5%: None of the measured endpoints indicated skin irritation: visual irritation score, skin reflectance spectrophotometer, transepidermal water loss and laser Doppler flowmetry	Yes	At least irritating to skin	Andersen et al 1995
n.a.	QSAR – Toxtree	n.a.	n.a.	n.a.	C8, C9, C10 fatty acid	Irritating or corrosive to skin	n.a.	Irritating or corrosive to skin	http://ecb.jrc.it/qsar/1
Rabbit	Primary skin irritation in albino rabbits, 5/group, Non GLP study from 1962	100%	0.01 ml/animal	24	C8 and C10 fatty acid	Severely irritating (no standard test, score 5 from 10)	Not reported	severely Irritating to skin	Smyth et al. 1962; Doc-III A6.1.4.s/01
Rat, 5 males and	Acute dermal toxicity test with Decanoic acid	25% in PEG	ca 30 (m); 27 (f)	24 h	C10 fatty acid	Skin reactions during daily observation for 15	Yes within 15 days	irritating to skin	TalviOja K. 2006; Doc III-A 6.1.2,

<sup>&</sup>lt;sup>1</sup> Model according to Gerner et al. 2004. QSAR Comb. Sci. 23: 726-733; Walker et al. 2005. QSAR Comb. Sci. 24:378-384; Hulzebos et al. 2005. QSAR Comb. Sci. 24 : 332-342

5 females	EEC B.3, OECD No. 402 GLP study from 2006		mg/cm2			days post exposure: All animals erythema grade 1 to 2 after application, developed into scaling and scabs (grade 1 to 2), completely reversible after 14 days of			
						observation.			
Mouse, 4 per dose group	LLNA, With Decanoic acid OECD 427 EEC B.42	In acetone:olive oil 4:1 70% 50% 25%	25µ1/ear	3 times in 3 consecutive days	C10 fatty acid	slight irritation no irritation no irritation	Not within 6 days	Mildly irritant	Weber 2006, Doc-III A6.1.5

Table 12b: Summary of data with C9 fatty acid as additional information for the evaluation of C8 and C10 fatty acids (data protected and not property of applicant for Octanoic and Decanoic acid)

Species, Number	Method	Conc.	Dose	Exp. time	Result	Revers. yes/no	Conclusion	Reference
Rabbit, 3 males	Dermal irritation test with Nonanoic acid EEC B.4, OECD No. 404 GLP	100%	75 mg/cm <sup>2</sup>	4 h	Average Score 24, 48, 72 hours Erythema: 4 Oedema: No scoring possible due to eschar formation, fissuring and/or brown discolouration of the skin	within 15 days Yes	Severely irritating to skin	Otterdijk van F.M. 2001c; additional information only since data owned by C9 fatty acid applicant W.Neudorff GmbH KG
Rat, 5 males and 5 females	Acute dermal toxicity test with Nonanoic acid EEC B.3, OECD No. 402 GLP	22% in PEG	ca 30 (m); 27 (f) mg/cm <sup>2</sup>	24 h	Skin reactions during daily observation for 15 days post exposure: All animals erythema 2/10 animals erythema up to grade 3 and 4 on single days (scale 1-4) All animals scabs and/or scales 7/10 animals scabs and/or scales up to grade 2	within 15 days: Erythema not reversible in 3/10 animals (grade 1 at day 15) Scabs and/or scales not	Severely irritating to skin	Otterdijk van F.M. 2001b; additional information only since data owned by C9 fatty acid applicant W.Neudorff GmbH KG

					on single days (scale 1-3) Clinical signs: Hunched posture, piloerection, chromod-acryorrhoea, lethargy, uncoordinated movements and/or shallow respiration were noted among all animals between days 1 and 5		reversible in 6/10 animals (grade 1 at day 15)		
Guinea pigs	GPMT, EEC B.6, OECD	corn oil	mg/cm <sup>2</sup>	24 h	24 and 48h	24 and 48h	n.a.	≥50% severely	Otterdijk van F.M.
animals/group:	No. 406; GLP; Epiderm.				Eryt. grade	Oedema grade		irritating	2001d; additional
2	exp. with Nonanoic acid:	100%	75		4	1			information only
2	Pretest	50%	37.5		4	1		2-10% mildly	since data owned
2		20%	15		2	0		irritating	by C9 fatty acid
2		10%	7.5		1	0			applicant
1		5%	3.75		1	0		$\leq 1\%$	W.Neudorff GmbH
1		2%	1.5		1	0		not irritating	KG
1		1%	0.75		0	0		to skin	
15	Main test	1%	0.15		0	0			

#### 4.4.1.4 Threshold for acute dermal irritation

For the <u>derivation of a threshold for acute dermal irritation</u> some studies from literature are summarized:

The clinical publication from Wahlberg et al. 1985 would be in agreement with an NOAEC estimate of 1%. From 100 hospitalised patients with various skin diseases exposed to 1% of the structurally related Nonanoic acid in propanol for 48 hours only 3 showed some skin irritation. The same publications reports that exposure of these 100 patients to a 5% solution resulted skin irritant in 35 patients. In Wahlberg et al. 1980 a 48 hours patch with 5% Nonanoic acid in propanol resulted skin irritant in 11 from 116 healthy human volunteers.

When Wahlberg 1983 applied 0.1 ml of 5, 10, 20, 40, 60 and 100% Nonanoic acid repeatedly for 15 days to his volar forearm, he did not find oedema development (as measured by skin-thickness) for concentrations up to 20% (in propanol). The same publication reports application of 5% Nonanoic acid in propanol to 3 guinea pigs for 15 consecutive days without oedema formation, but the application to one rabbit resulted in significant oedema. However these publications do not address at all if erythema was visible.

Within the Local Lymph Node Assay Decanoic acid was applied to the mouse ear for 3 consecutive days. It induced mild irritation only at concentrations of 70%. A GPMT carried out with Nonanoic acid showed skin irritation after epidermal application for 24 hours only with concentrations above 1%.

Andersen et al 1995 reports test results that aim to contribute to the development of objective tests for human skin irritation. Eight healthy Caucasian volunteers were (after informed consent) exposed for 24 hours to the structurally related Nonanoic acid in concentrations of 2.5%, 5%, 10% and 20% in propanol. Skin irritation was measured 20 minutes after patch removal by visual irritation score, skin reflectance spectrophotometer, transepidermal water loss and laser Doppler flowmetry. None of the endpoints mentioned above indicated skin irritation for concentrations of 2.5% or 5%.

Branco et al 2005 investigated hypo- or hyperreactivity to skin irritants after repeated exposure. The sodiumsalt of the structurally related C12 carbonic acid (Sodium-dodecyl-sulfate, SDS) was applied to seven healthy Caucasian volunteers (after informed consent) in concentrations of 0.025%, 0.05% and 0.075% in water continuously for 5 days per week, 3 consecutive weeks, then 3 weeks of break and again 3 weeks of the same exposure regime. After each day of exposure the skin was analysed and the substance was renewed. Also after the first exposure break and 2 and 5 weeks after the last exposure the skin was analysed. Skin reaction was analysed by visual scoring, transepidermal water loss, capacitance, skin colour reflectance and laser Doppler flowmetry. Skin reactions increased with repeated exposure but after the exposure breaks of 3 or 2 weeks all endpoints returned to basal levels. Considering the structural similarity of SDS (salt of C12 carbonic acid) and Octanoic and Decanoic acid and assuming that both substances induce irritation by direct cytotoxicity and consequent inflammatory reactions the data summarized for SDS support that also with Octanoic and Decanoic acid adaptive reactions after repeated exposure are unlikely.

In summary there is evidence (in terms of incidence, magnitude and reversibility of skin irritation effects) that a Octanoic and Decanoic acid concentration of 1% may be a suitable point of departure for the derivation of an acceptable exposure level, at least for acute, dermal local effects. However, according to TM 2009 no acute local AECs are necessary for risk assessment. The respective risk is considered to be sufficiently assessed and managed by the respective assignment of R- and S-phrases, or H- and P- statements (GHS).

The uncertainty of this point of departure for quantitative estimation of medium or long term dermal local thresholds lies within the question if or how much lower this point would be with daily repeated dermal exposure (actual database does not exceed 48 hours of application). The RMS-AT is not aware of data based assessment factors to address this uncertainty. However at least there is some evidence that it is unlikely that adaptive reactions will develop after repeated exposure to Octanoic or Decanoic acid (endpoints return to basal levels after some weeks of break)

The uncertainty of a point of departure derived from new dermal repeated dose studies in animals would lie within the question if and how semi-occlusive conditions in the animal test can be translated to realistic human exposure situations and if the amount per treated skin area is realistic. Furthermore interspecies uncertainty would need to be accounted; TM 2009 proposes as a general rule an assessment factor (AF) of 1 for local dermal effects but also indicates that uncertainty of local AF can be very high and adjustments

should be done with caution. The respective empirical database is very limited. Therefore it may be interesting that several publications are available indicating that acute dermal irritation studies in rabbits show a sensitivity of about 100% but specificity of or below 50% for the prediction of 4h-human-patch-test data. The new in vitro human skin method EU-B46 (full replacement of in vivo method) seems to perform superior (see e.g. Jirova et al. 2007, Basketter et al. 2004<sup>2</sup>). However the RMS is not aware of any discussion of the implications of these data for interspecies uncertainty estimates for local dermal repeated dose NOAECs.

Also intraspecies uncertainty would need to be accounted. TM 2009 proposes as general rule an AF of 10 or less for local dermal effects, depending on the knowledge of mechanism and knowledge on respective human variation. Fluhr et al. 2008 reviews that dermal irritation is not an immunologic inert process but involves different cytokines and intercellular interactions but provides just qualitative information on individual and environment related variables. Basketter et al. 1996 reports substantial human intraspecies differences for acute local effects with SDS.

However Fluhr et al. 2008 references also the importance of the barrier function of the skin for irritation effects and the necessity to consider synergistic effects with mechanical or physical stress or other substances.

The latter also means that the product formulation (including pH adjustment and solvent selection) may have a significant impact on the dermal irritation potential, which means that data for the active substance may contain high uncertainty for product risk assessment. In the specific case of Nonanoic acid (considered relevant for Octanoic acid and Decanoic acid by read across) the dermal data basis includes mainly studies with Nonanoic acid in propylene glycol. However the final representative products contain Octanoic acid and Decanoic acid and 10% in water or -with higher concentrations- in water/ethanol/isopropanol mixture. All products contain emulgators, some products contain a preservative, some are pH neutralized others contain high amounts of strong acids rendering the product corrosive.

It should also be considered that skin irritation may be quantified by various methods and endpoints showing different sensitivity. Fluhr et al. 2008 discusses several approaches to quantify skin irritation covering endpoints of heat, redness, swelling, pain and dysfunction and he regards a multiparametric approach in the evaluation of irritant reaction as adequate.

In summary the actual point of departure (1%) for the estimation of local dermal effects of Octanoic acid and Decanoic acid is based on human literature data with Nonanoic acid and SDS (for up to 48 hour applications) which is in agreement with guinea pig test data for Nonanoic acid (irritation NOAEC from 24 hour application in GPMTs) and conservative when considering mouse data with Decanoic acid (LLNA application for 3 consecutive days, irritation threshold  $\geq$  50%, Doc III-A 6.1.5). The derivation of an acute local dermal AEC is not needed since acute effects should be addressed by respective classification and labelling. The derivation of longer term local dermal AECs from these data would contain uncertainty with regard to the necessity to extrapolate from acute to longer term scenarios and with regard to the fact that the product composition may have a substantial influence. However new dermal repeated dose data from animals (expectedly achievable only for a.i.) would contain other uncertainties with regard to differences between active substance and product formulation. Therefore – in case necessary and adequate- a qualitative risk assessment with regard to local skin effects may be preferred. The available data may be taken into consideration including the uncertainties described.

Furthermore for all wet-work places integrated skin protection programmes including prevention, early recognition and medical care should be regular practice in order to control risk for dermal irritation.

<sup>&</sup>lt;sup>2</sup> For the 4h-HPT 30 human volunteers are exposed to the substance with 0.2g/25mm plain Hill chamber for up to 4 hours. As soon as weak but unequivocal erythema is observed exposure is stopped in the respective individual and counted as positive response. The substance is considered as skin irritant (R38), when the incidence of positive irritation reactions to the undiluted test substance is statistically significantly  $\geq$  the level of reaction in the same panel of volunteers to 20% SDS (see Basketter et al. 1997, York et al. 1996, Robinson et al. 2001).

#### 4.4.1.5 Comparison with criteria

The in vitro data and human in vivo data support classification for GHS skin irritation category 2. Please see above, chapter 4.4.1.3.

#### 4.4.1.6 Conclusions on classification and labelling

Considering all available information with regard to skin corrosion or skin irritation Decanoic acid should be classified as skin irritant, R38 according to EC criteria or as skin irritation category 2 according to GHS.

#### 4.4.2 Eye irritation

#### 4.4.2.1 Non-human information

Species	Method	Scoring Syste	m		Result	Reversibility yes/no	Reference
Rabbit, 5/group	Not reported Non-GLP publication from 1962	Grade 1	Grade 5	Grade 10	Grade 9, indicating risk for serious damage to eye (R41 or H318)	Not reported	Smyth et al. 1962; Doc-III A6.1.4.e/1
		very small area of necrosis	burn	severe burn			
rabbit	Not reported Non-GLP publication from 1976	-	-	-	corneal opacity and moderate conjunctivitis	No reversibility up to 72 hours	Briggs et al. 1976

Table 13: Summary of octanoic acid eye irritation for Octanoic and Decanoic acid

#### 4.4.2.2 Human information

Not available.

#### 4.4.2.3 Summary and discussion of eye irritation

For the estimation of **eye irritation** hazard no studies are available for Octanoic acid or for Decanoic acid. A severe skin irritation would, according to OECD guideline 405, exclude further eye irritation testing with animals and result in classification as severely eye damaging. Furthermore two publications were identified (see table 13) attributing score 9 from 10 for corneal necrosis or indicating corneal opacity and no reversibility up to 72 hours for Decanoic acid. The same data are presented for Octanoic acid.

New in vitro eye corrosion test data would be needed to classify Decanoic acid as irritating to eyes, R36 according to EU scheme or category II, H318 according to GHS

Several in vitro tests for severe eye damage are validated and recommended in the European Manual of Decisions for Classification and Labelling (BCOP, ICE, RRET-IRE, HET-CAM) and the Bovine Cornea Opacity Test (BCOP) and the Isolated Chicken Eye Test (ICE) are also adopted as OECD TG. Since it is clear from the available data that the substance is at least eye irritating, a negative e.g. BCOP test should be sufficient to conclude on classification of Octanoic and Decanoic acid as eye irritant (R36 or Cat II H319).

#### 4.4.2.4 Comparison with criteria

For the estimation of eye irritation hazard no OECD standard studies are available for Octanoic acid or for Decanoic acid. A severe skin irritation would, according to OECD guideline 405, exclude further eye irritation testing with animals and result in classification as severely eye damaging. Furthermore two publications were identified, attributing score 9 from 10 for corneal necrosis (Smith et al. 1962, no information on reversibility) or indicating corneal opacity and no reversibility up to 72 hours (Briggs et al 1976) for Decanoic acid. These references summarize the same results for Octanoic acid. According to the actual GHS criteria category 1 would result from a corneal score of 3 (from maximum 4) in at least 2 of 3 tested animals or non reversibility of corneal effects in at least one animal. Considering the observation of a corneal score of 9 (from maximum 10) and no observation of reversibility Decanoic acid needs to be classified for risk of severe damage to eye (R41) according to DSD criteria or eye irritant category I (H318) according to GHS.

#### 4.4.2.5 Conclusions on classification and labelling

Decanoic acid needs to be classified for risk of severe damage to eye (R41) according to DSD criteria or eye damage category I (H318) according to GHS.

#### 4.4.3 Respiratory tract irritation

#### 4.4.3.1 Non-human information

No specific data available.

#### 4.4.3.2 Human information

No specific data available

#### 4.4.3.3 Summary and discussion of respiratory tract irritation

Considering the strong skin and eye irritation properties of Octanoic acid and Decanoic acid also respiratory irritation hazard has to be assumed. However the only available quantitative information for effects via inhalation stems from acute inhalation studies and is summarized in chapter 4.2. The available data are not sufficient for classification for respiratory irritation (STOT – single exposure, category 3) since the GHS supports respective classification only when largely based on human respiratory data.

The data are **insufficient to derive a local respiratory AEC**. However it is likely that with an acute exposure of 1mg/L Nonanoic acid as ammonium salt (relevant for Octanoic acid and Decanoic acid by read across) no severe respiratory irritation occurred in the rat: Within rats no clinical signs and no macroscopic pathological effects were observed after 4 hours of exposure to 1 mg/L Nonanoic acid as ammonium salt within a formulation (pH 7) containing additionally Maleic hydrazid with 3%. The overall database for Octanoic acid, Nonanoic acid and Decanoic acid indicates a

respiratory LC50 > 5 mg/L (see Doc II-3.2). As mentioned the data are insufficient for classification for respiratory irritation (STOT –SE).

The derivation of a local respiratory AEC from these data would contain uncertainties with regard to the extrapolation from acute to medium or long term exposure and the fact that necropsy was not carried out at the end of exposure but after 14 days of observation and no respiratory histology and/or functional tests are available for the acute study. Furthermore extrapolation from rat to human has to be accounted (airway anatomy, respiratory rate, deposition patterns and consequently local and total clearance rates). From Kalberlah et al 2002 and ECETOC 2003 and as concluded in TM 2009 humans may be considered on average marginally more sensitive than rats and an uncertainty factor of 2.5 may be adequate. However the empirical data base for this interspecies uncertainty factor for local respiratory effects is very weak, just as it is the case for the human intraspecies variability (TM 2009 proposal 10 or less).

Furthermore product formulation may have a very significant influence on irritation thresholds. In the specific case of Octanoic, Nonanoic and Decanoic acid the inhalation data basis includes studies with the free acids and with the ammonium salt. However the final representative products contain Octanoic acid and Decanoic acid in concentrations between 3% and 10% in water or -with higher concentrations- in water/ethanol/isopropanol mixture. All products contain emulgators, some products contain a preservative, some are pH neutralized others contain high amounts of strong acids rendering the product corrosive.

Since new repeated dose inhalation tests can usually only be obtained for active substances but not for individual products and considering the significant influence that product formulation may have on local irritancy it is proposed that – in case needed and appropriate- a qualitative risk assessment with regard to local respiratory effects of the product may be preferred. The available data may be taken into consideration including the uncertainties described.

#### 4.4.3.4 Comparison with criteria

Considering the strong skin and eye irritation properties of Octanoic acid and Decanoic acid also respiratory irritation hazard has to be assumed. However the only available quantitative information for effects via inhalation stems from acute inhalation studies and is summarized in chapter 4.2. The available data are not sufficient for classification for respiratory irritation (STOT – single exposure, category 3) since the GHS supports respective classification only when largely based on human respiratory data.

#### 4.4.3.5 Conclusions on classification and labelling

No classification necessary.

#### 4.5 Corrosivity

See chapter 4.4

#### 4.6 Sensitisation

#### 4.6.1 Skin sensititsation

#### **4.6.1.1** Non-human information

Table 15a: Summary of animal skin sensitisation data for the evaluation of Octanoic acid and Decanoic acid

Species	Method	Substance tested	Result	Conclusion	Reference
Mouse	Local lymph node assay	C8 fatty acid	Dose/ SI 10 /0.7 25 / 1.0 50 / 1.6 Vehicle acetone-olive oil	Not sensitizing	Gerberick et al. 2004 Doc III-A 6.1.5/1
Mouse	Local lymph node assay OECD 429, EU B.42 Vehicle acetone:olive oil	C10 fatty acid	Dose / SI 25% / 3.3 50% / 2.7 70% / 4.9 erythema Control HCA 25% / 12.2	Weight of evidence evaluation: not sensitizing	Weber 2006; Doc- III-A 6.1.5/2

#### 4.6.1.2 Human information

Table 15b: Summary of human skin sensitisation data for the evaluation of Octanoic acid and Decanoic acid

Human	25 volunteers, 1% concentration; occlusive application for 5 alternate 48 hour periods. 10-14 day after treatment, challenge was performed.	C8 fatty acid	0/25 volunteers sensitized	Not-sensitizing, but low relevance because of low test concentration and since no information about ethical criteria explicit.	Cited in BIBRA 1988
Human	Human maximisation test, 28 volunteers, 1% concentration Occlusive application of test material for 5 alternate 48 hour periods. 10-14 day after treatment, challenge was performed.	C10 fatty acid	0/28 volunteers sensitized	Not-sensitizing, but low relevance because of low test concentration and since no information about ethical criteria explicit.	Cited in Opdyke 1979 and IUCLID 2000 (probably identical reference)

#### 4.6.1.3 Summary and discussion of skin sensitisation

Sensitisation tests with Octanoic acid and with Decanoic acid performed with human volunteers (referenced in Bibra 1988, Opdyke 1979) did not indicate a skin sensitisation potential. However the tests were carried
out with 25 or 28 human volunteers, respectively and just a 1% solution, which is very low. Moreover neither study reports nor full publication and no information on the coherence with ethical principles for human testing is available. Therefore these references are of very limited value for hazard assessment.

Gerberick et al. 2004 reports a negative LLNA for Octanoic acid. However no full publication or study report is available and Octanoic acid was tested only up to concentrations of 50%.

Consequently a new LLNA study according to OECD 429/EU B.42 and GLP was performed with 70% of Decanoic acid in acetone: olive oil. Since this study resulted borderline to positive a total weight of evidence evaluation was proposed by the applicant.

The evaluation concludes that neither Octanoic acid nor Decanoic acid are sensitizing based on the following considerations:

- The LLNA conducted with Decanoic acid (GLP study from 2006) at concentrations of 25%, 50% and 70% in acetone: olive oil (AOO, 4:1 v/v) resulted in a stimulation index (SI) of 3.3., 2.7, 4.9 respectively. The positive control with 25% hexyl-cinnamic-aledehyde (HCA) resulted in an SI of 12.2. The EC3 value is 53%, indicating that Decanoic acid is according to the LLNA –if at all- a very weak sensitizer.
- The Health& Safety Executive Report 399/2001 on "Development of the local lymph node assay fro risk assessment of chemicals and formulations" contains information on the inter-laboratory and temporal stability of SI values of 25% HCA (positive reference used) and the influence of vehicle and formulation on LLNA response. The reported SI for the three laboratories are 7.2 to 13.9 (mean 9.0), 4.0 to 8.8 (mean 6.5) and 3.8 to 8.5 (mean 6.6) showing that the positive reference SI of 12.2 is on the high side. The laboratory conducting the LLNA with Decanoic acid showed comparable historical reference data indicating that the negative control dpm (disintegration-per-minute) values are within the lower 5th percentile of the historical control range resulting in a higher SI. That results shows that the test is likely on the very sensitive side.
- The example of dimethylamino-propylamin (DMAPA) results in the LLNA (as provided in the presentation of Peninks 2007) and the report cited above show that the vehicle can have enough influence on the SI to reach a slightly elevated level exceeding 3.0 by influencing the skin permeation. AOO (recommended in the validated LLNA as first choice and used in the test for decanoic acid) like ethanol is known to lessen the skin barrier for lipophilic substances.
- The purity of the active substance Decanoic acid tested and the purity of Octanoic acid and Decanoic acid marketed is relatively high (within the LLNA: 99.6% C10 and 0.2 % C8; in 5-batch analysis: 99 % C10, 0.67 % C8, 0.08 % C6, 0.04 % C12) indicating that it is very unlikely that impurities cause a positive response.
- There are no reports that medium chain fatty acids have caused skin sensitisation in humans, though the applicant states that Decanoic acid is used in cosmetics and biocides (Octanoic acid or Decanoic acid are not part of Annex III (list of skin sensitizers) of the Cosmetic Directive; concentrations of use are not public available the biocidal products on the market contain up to 20 % decanoic acid.
- Published results indicate that octanoic acid is non-sensitizing in the LLNA up to a concentration of 50% (higher concentrations not tested, Gerberic et al 2004).
- Octanoic acid and Decanoic acid lacks structural properties, which would cause interactions with proteins. That opinion is supported by the results of the OECD Toolbox. The results on the skin metabolism (only simulated data are available) also do not indicate that a metabolite would cause the observed elevated SI. (However, the acetone part of the solvent (acetone/olive oil, 4:1) has structural properties which are known to cause protein binding through nucleophilic addition to ketones.)
- Octanoic acid and Decanoic acid are ubiquitously present in most species including humans and a fast natural metabolism into other medium chain fatty acids is textbook knowledge.
- The chosen concentrations in the LLNA (low dose, 714 mg/kg/day, total 2143 mg/kg, mid dose, 1366 mg/kg/day, total 4098 mg/kg and high dose, 1975 mg/kg/day, total 5924 mg/kg) do lead to high body burden (for a 60 kg adult person to about 120 g) which are not expected to stay for a significant time on human skin because of the irritating properties of the medium chain fatty acids.

- In literature positive results with the local lymph node assay (LLNA) are reported for Nonanoic acid (Montelius et al. 1998), but at the same time these results are described as false positive (Montelius et al. 1998); further discussion of false positive and negative results from LLNAs and GPMTs are in line with this perception (see e.g. Basketter et al. 1998, 2007a and b, Kreiling et al. 2008) and further methodical improvements of the LLNA are under discussion (see e.g. Ku et al. 2008, Loveren et al. 2008) which should be fostered by other research aimed at improving the mechanistic understanding of sensitisation (see e.g. Aeby et al. 2008).
- The RMS has a guinea pig-maximisation-test (GMPT, OECD-GLP study from 2001, data owned by different applicant) in hands for Nonanoic acid (that was submitted for the biocides review for PT 19 as cat-repellent) which is clearly negative.

Considering the negative LLNA for Octanoic acid up to 50%, the high concentrations of 50 or 100% needed for positive response in the LLNA for Decanoic acid and giving preference to the consideration that these linear carbonic acids do not contain structural alerts necessary for protein interaction as well as the high purity of technical Octanoic acid and Decanoic acid (see confidential Annex) none of these two medium chain fatty acids should be classified as skin sensitising. This decision is in agreement with the negative results of the Guinea Pig Maximisation Test with Nonanoic acid.

#### 4.6.1.4 Comparison with criteria

A total weight of evidence evaluation is provided. Please see chapter 4.6.1.3.

#### 4.6.1.5 Conclusions on classification and labelling

No classification is necessary.

#### 4.6.2 Respiratory sensitisation

No data are available to estimate the hazard for repiratory sensitisation. However it is assumed that the main toxicological mechanism of action is irritation by direct membrane destruction and there are no metabolites of concern

#### 4.7 Repeated dose toxicity

#### 4.7.1 Non-human information

No standard guideline studies are available for this endpoint. However toxicological information is available from several nutritional studies performed with medium-chain triglycerides (MCT). As described in chapter 4.1 MCTs easy absorption and endogenous metabolism represents textbook knowledge that should be taken into account for discussion of potential adverse effects.

For repeated dose oral exposure two studies are summarised in more details (see table 17a below):

Webb et al. 1993 (see Doc III-A 6.4.1.1/01) published a sub-chronic feeding study in rats with caprenin, a randomized triglyceride primarily comprising caprylic (octanoic) acid (C8:0), capric (decanoic) acid (C10:0) and behenic acid (C22:0). Caprenin was administered in a semi-purified diet to weanling rats (25/sex/group) at dose levels of 5.23, 10.23 and 15.00% (w/w) for 91 days. Corn oil was added at 8.96, 5.91 and 3.00%, respectively, to provide essential fatty acids and digestible fat calories. Corn oil alone (12.14%) and a blend of medium-chain triglyceride (MCT) oil plus corn oil (11.21 and 3.13%, respectively) served as controls. All diets were formulated to provide about 4000 kcal/kg of diet and 26.8% of digestible calories from fat by

assuming that corn oil, MCT oil, and caprenin provided 9,7 and 5 kcal/g, respectively. Survival, clinical signs, body weight, feed consumption, feed efficiency, organ weights, organ-to-bodyweight ratios, organ-to-brain-weight ratios, haematological values and clinical chemistry parameters were evaluated in all groups. Histopathology of a full complement of tissues was evaluated in the corn oil and MCT oil control groups as well as the high-dose caprenin group. Additional rats (n = 5/sex/group) were included in the study to determine whether there was marked storage of C22:O in heart, liver or perirenal fat at the end of the 91-day feeding period. No significant differences in body weight gain were measured with the balanced caloric diets, although feed conversion efficiency was reduced in the high-dose caprenin group. No adverse effects from the ingestion of caprenin were detected, nor were significant amounts of C22: O present in the fat extracted from the selected fat depot sites. These results establish a no-observable adverse- effect level (NOAEL) of more than 15% (w/w) caprenin in the diet (or more than 83% of total dietary fat), which is equal to a mean exposure level of more than 13.2 g/kg/day for male rats and more than 14.6 g/kg/day for female rats. Considering that C8 and C10 fatty acids are structurally tightly related and share the same metabolism this may be translated to a common NOAEL of  $\geq$  7000 mg/kg bw for Decanoic acid and Octanoic acid.

Harkins et Sarett 1968 (see Doc III-A 6.4.1.1/02) published a nutritional evaluation of a medium chain triglyceride (MCT) preparation. A casein diet, containing 18.5% MCT and 2.5% safflower oil, the latter to supply essential fatty acids, was compared with similar diets containing conventional dietary fats. The MCT contained about 51% octanoic acid and 35% decanoic arid resulting in an octanoic acid dietary dose of about 4700 mg/kg bw day and a decanoic acid dietary dose of about 3200 mg/kg bw day. Data obtained in a 47-week study showed that the MCT diet supported normal growth and development. At autopsy carcass composition (without liver, heart, epididymal fat pads, GI) in terms of weight, fat, protein and ash levels were similar to those in rats fed with conventional fats. Also organ weights of liver, kidney, spleen, heart, adrenals, femurs and testes were similar in all groups. Histological study showed that intestinal and liver sections were normal after 47 weeks on the MCT-containing diet. In general, rats fed MCT had slightly lower growth rates and caloric efficiency values, less carcass fat and smaller epididymal fat pads than animals fed conventional dietary fats. Little C8 and Cl0 were found in depot fat that is 0.5 and 4.9%, respectively, though these fatty acids comprised about 85% of the dietary fat. The MCT diet also supported normal reproduction, as indicated by litter size and number. For Decanoic acid and Octanoic acid a common NOAEL of  $\geq$  8000 mg/kg bw day is apparent in this study.

Route	duration of study	Species Strain Sex no/group	dose evels [g/kg bw day] frequency of application	Results	LO(A)EL	NO(A)EL	Reference
Oral (feeding of caprenin (triclyceride) consisting to 26.6% of Decanoic acid and 23.2% Octanoic acid)	91 days	Rat Sprague- Dawley, 25 sex/group	Low dose C10: 1.17 (m); 1.3 (f) Low dose C8: 1.02 (m); 1.14 (f) mid-dose C10: 2.3 (m); 2.5 (f) mid-dose C8: 2.02 (m); 2.25 (f) high-dose C10: 3.5 (m); 3.9 (f) high-dose C8: 3.06 (m); 3.39 (f)	No adverse effects caused by Decanoic acid or Octanoic acid in form of caprenin	-	≥ 7000 mg/kg bw/day	Webb, 1993 Doc III A6.4.1.1/01
Oral (feeding of medium-chain triglycerides (MCT)	2 generatio ns	Rat, Wistar, 15 sex/group	40% of daily calories in food supplied by MCT (assuming default	No adverse effects caused by Decanoic acid and Octanoic acid	-	≥ 8000 mg/kg bw/day	Harkins, 1968 Doc III- A6.4.1.1/02

Table 17a: Summary of Decanoic acid and Octanoic acid repeated dose toxicity data

containing 35% Decanoic acid and 51% Octanoic acid)		food conversion factor between 0.1 and 0.05 equivalent to ca. 8 g/kg bw/day Decanoic+Octano	in form of medium-chain triglycerides		
		ic acid)			

Traul et al 2000 references also several other animal studies with MCT: a 3 week dietary toxicity study in chicks, a 30 day oral gavage study in rats, a 90 day parenteral study in rabbits, another 3 months dietary study in rats and three six week studies in rats. Most of these studies are performed for the purpose of nutrition and special attention to changes in the fatty acid metabolism, weight gain or blood parameters like cholesterols were given. Compared to a diet containing long-chain fatty acids, which represent a higher caloric value, reduced weight gain has been reported, but if corrected for caloric intake no significant derivations are observed. The results are in line with those detailed above.

Traul et al 2000 references also human studies which indicate no toxicological symptoms from MCT repeatedly applied for up to 10 days with doses up to about 1000 mg MCT/kg bw day. Traul et al 2000 discusses also the potential for ketosis but concludes that there is no risk, even with high dietary MCT doses [~ g/kg bw].

The applicant provided also a publication from Mori 1953 indicating that dietary doses of 5000 - 10000 mg Octanoic acid and Decanoic acid per kg bw for 150 days did not induce any pathological changes in the rat forestomach or glandular stomach. However the study does not indicate that also other endpoints were analysed. WHO/IPCS 1998 gives also reference to this publication and others indicating repeated dose NOAELs for hexanoic, decanoic and lauric acid of higher than 1000 mg/kg bw day.

For the evaluation of Nonanoic acid in the context of the BPD 98/8/EC the respective applicant W. Neudorff GmbH KG submitted a subacute 4-week oral toxicity study. The study is owned by W. Neudorff GmbH KG and data protected, however since the data requirement for repeated dose studies is fulfilled with the references provided above and the study is not used for the advantage of the applicant of decanoic and octanoic acid (Fatty Acid Consortium) it may be cited and discussed also for the evaluation of Decanoic acid and Octanoic acid: Male and female Wistar rats received Nonanoic acid at doses of 0, 50, 150 or 1000 mg/kg bw/day by gavage in concentrations of 1%, 3% and 20% in Propylene glycol as vehicle. Propylene glycol was used as vehicle. No test substance related mortalities occurred. In week 3 on some occasions breathing difficulties in the form of rales and/or gasping were evident for most animals of the high dose group. In animals of the two other dose groups, no treatment related clinical signs of toxicity were observed. Body weight and body weight gain of treated animals remained in the range of control animals. There was only slightly lower food consumption for the high dose females in week 3, however since food intake was normal again in week 4 this was considered to be without toxicological relevance. No treatment related changes were observed with the functional examinations of hearing ability, papillary reflex, static righting reflex and grip strength and within the motor activity test. Haematological and clinical chemistry findings did not reveal any treatment related differences. Absolute and relative organ weights showed no dose-related changes. An irregular surface of the forestomach was noted at all high dose animals. In this dose group, histopathological examination showed slight to marked hyperplasia of the squamous epithelium of the forestomach. These latter effects were also noticed at 2 from 10 animals of the mid-dose group but these were considered to be without any toxicological relevance since they were minimal and occurred in the absence of (other) functional/morphological disturbances or clinical signs. Therefore a local oral NOAEC of 3% at a dose of 150 mg/kg bw/day was established (Doc III-A 6.3.1).

As additional information a study summary of a range finding study from U.S. EPA may be referenced (no study report or letter of access available): Nonanoic acid was administered in the diet for 14 days to male and female Sprague-Dawley rats at 0, 1500, 2500, 4000, 6300, 7500 or 20000 ppm, corresponding to 0, 145, 267, 423, 633, 753 or 1834 mg/kg bw/day, respectively. No systemic toxicity was seen in either sex at any dose level; treatment had no adverse effect on survival, clinical signs, body weight, body weight gain, food consumption, haematology, clinical chemistry or gross pathology, but no histopathology was carried out.

Route	Duration of study	Species Strain Sex no/group	Dose levels, frequency of application	Results	NOAEL	Reference
Oral	28 days	Wistar rat, Crl:(WI) BR (outbred, SPF- Quality), 5 males and 5 females per dose group	Dose level of either 50, 150 or 1000 mg/kg bw/day, per gavage	1000 mg/kg bw day macroscopically irregular surface of the forestomach confirmed by microscopic hyperplasia of the respective squamous epithelium. 150 mg/kg bw day minimal hyperplasia of squamous epithelium of fore stomach (2 males, no other effects observed)	≥ 1000 mg/kg/day	Doc III-A 6.3.1; Otterdijk 2002, GLP Study, data protected; owned by W. Neudorff GmbH KG

Table 17b: Repeated	dose toxicity tests with	Nonanoic acid (read	across to Decanoic and	d Octanoic acid)
The second secon				

The effects on the squamous epithelium of the forestomach, which were a macroscopic irregular surface and a microscopic hyperplasia, were induced at the highest tested dose of 1000 mg/kg bw/day when applied daily for 28 days by gavage as a 20% solution in propylene glycol.

However as mentioned above within the 14 days study (Kuhn 1995, Study summary from EPA, no letter of access for the applicant available) the macroscopic effect on the forestomach was not observed even at higher doses of up 1834 mg/kg bw/day administered at concentrations of 20000 ppm (corresponding to 2%) in food. Also Mori 1953 did not find any pathological effects in the forestomach or glandular stomach for octanoic and decanoic acid dietary applied in concentrations of 5000 to 10 000 mg/kg bw day for 150 days.

The difference between the three study results cited above may be explained by the way of application (dietary vs. gavage): The capacity of the chow pulp to buffer the irritation property of Nonanoic acid could have contributed to the lack of forestomach effects in the Kuhn 1995 and Mori 1953 publication. In addition the lack of effects within these two studies was not verified by histological analysis.

However the effect on the forestomach was the only potentially toxicologically relevant effect observed in the oral repeated dose studies. This effect is assumed to be associated with its local irritant property rather than by systemic action. Therefore the LOAEL of 1000 mg/kg bw day based on the hyperplasia of the squamous epithelium of the forestomach in the 28-day gavage study and the respective NOAEL of 150 mg/kg bw day are not suitable for the derivation of a systemic AEL.

## 4.7.2 Human information

Traul et al 2000 references also human studies which indicate no toxicological symptoms from MCT repeatedly applied for up to 10 days with doses up to about 1000 mg MCT/kg bw day. Traul et al 2000 discusses also the potential for ketosis but concludes that there is no risk, even with high dietary MCT doses [~ g/kg bw].

#### 4.7.3 Summary and Discussion of repeated dose toxicity

In summary- though medium chain fatty acids (including C8, C9, C10) were applied as repeated dose up to 10 000 mg/kg bw day no systemic LOAEL can be derived from the toxicological studies. The assumption of a low toxicological concern for systemic effects of medium chain fatty acids is plausible. Daily human uptake of fatty acids as food contents is, e.g. according to Henderson et al 2003 about 900 mg/kg bw day and the metabolic pathways are similar for all fatty acids, that is complete catabolism for energy supply or

conversion to fat suitable for storage (see also chapter 4.1). In addition estimates of uptake as natural food content specific for Decanoic acid and Octanoic acid were submitted (see chapter 4.1).

In the absence of a systemic LOAEL from toxicological studies and taking into consideration the ubiquitous nature of fatty acids and their common metabolic pathways it seems appropriate to estimate the systemic AEL based on the highest systemic NOAEL from the longest available repeated dose study. The publications from Webb 1993, Harkins 1968, Traul et al 2000 for medium chain triglycerides (MCTs) as well as the publications from Mori 1953 and WHO/IPCS 1998 for the free fatty acids would support NOAELs above 1000 mg/kg bw day. However the 28 day study with nonanoic acid indicating a NOAEL of  $\geq$  1000 mg/kg bw day is more robust, since it was carried out with the free fatty acid and with GLP and OECD test guideline standards. Consequently a systemic NOAEL of 1000 mg/kg bw day is proposed.

#### 4.7.4 Other relevant information

#### Local AECs

A somewhat different approach may be necessary for the derivation of a local-oral AEL: In the available 28 day rat gavage study with the structurally related Nonanoic acid local-oral effects were observed as forestomach irritation with a NOAEL of 150 mg/kg bw day at a concentration of 3% in propylene glycol.

In principle the relevance of this finding for human risk assessment is questionable (Wester et al. 1988, IARC 1999, ECETOC 2006, Proctor 2007). A human counterpart for the rodent forestomach does not exist: The epithelia of the rodent forestomach are not identical to the epithelia of the human oesophagus or stomach. The rodent forestomach is a cornified stratified squamous epithelium without glands. In contrast the human oesophagus is a non-keratinizing stratified squamous epithelium with submucosal glands (providing some protection of the epithelium by mucus secretions) and the human stomach is lined by columnar epithelial cells with diverse glands. The rodent forestomach has a medium pH between 4.5 and 6, the human esophagus has a pH of 7 and the human stomach a pH of 1 to 2 (fasting). But probably most important, the contact time between the oesophagus epithelium and Nonanoic acid is negligible in humans when compared to the rodents' forestomach, which functions as a storage organ. The contact time in the human stomach and intestine may be significant, as is the contact time in the rodent glandular stomach and intestine. Therefore, it was suggested that no-observable-effect levels should be determined in those parts of the gastro-intestinal tract having a counterpart in humans, such as pharynx and oesophagus (Harrison 1992) or glandular stomach or intestine. No effects were observed in these tissues within the rat 28 day gavage study.

Consequently it is assumed that the 28 day NOAEC for forestomach irritation in the rat is – if at all relevantat least a conservative point of departure for estimating local oral effects in humans. Therefore a local-oral AEC may be derived from the local NOAEC without the application of kinetic and dynamic interspecies factors and without a kinetic intraspecies factor. However local irritation effects may be significantly influenced by product composition attributing additional uncertainty to the local oral AEC. In the specific case of Nonanoic acid (relevant for Octanoic acid and Decanoic acid by read across) the oral data were generated with Nonanoic acid in propylene glycol. However the final representative products contain Octanoic acid and Decanoic acid in concentrations between 3% and 10% in water or -with higher concentrations- in water/ethanol/isopropanol mixture. All products contain emulgators, some products contain a preservative, some are pH neutralized others contain high amounts of strong acids rendering the product corrosive. Consequently there may be high uncertainty in the threshold extrapolation from the carbonic acid to the final product.

No studies for the derivation of local-dermal or local-inhalation AELs for medium or long term exposure situations are available. For discussion of the data to be consulted for a qualitative risk assessment with regard to local dermal and local respiratory effects see chapter 4.4.

#### Waiving of chronic studies

The conduct of chronic toxicity studies was considered not to be necessary based on the following considerations:

- The detailed knowledge of the metabolic pathways that are similar for all fatty acids: complete catabolism for energy supply or conversion to fat suitable for storage (see chapter 4.1).
- The lack of toxicologically relevant effects also at the very high doses in the available oral repeated dose studies
- The results from the acute mammalian toxicology studies, indicating only concern for skin and eye irritation
- No genotoxicity supported by the evaluation of the three standard in vitro genotoxicity tests (see chapter 3.6. below) with Decanoic acid and with Octanoic acid.
- The nature of Decanoic acid and Octanoic acid that are linear saturated fatty acids and the ubiquity of these and other similar fatty acids in nature: Decanoic acid and Octanoic acid are naturally present in many types of food in its free form or as triglyceride (see Gubler 2006, Ref A 6/05). Uptake as natural food source from cheese or coconut oil may be estimated to be significantly above 20 mg/ person day (=estimation from average Swiss cheese consumption; 178 mg decanoic acid and 200 mg octanoic acid and 750 mg octanoic acid per person and day = estimation from 100 g sheep cheese; see Document III-A 6.5.1 and 2). The latter four estimates are in the range of the proposed AEL. The daily human uptake of total fatty acids as food contents may be estimated e.g. according to Henderson et al 2003 and Ruston et al. 2006 in the range of 900 mg/kg bw day (see chapter 4.1). This may further support the high AEL for Decanoic acid and Octanoic acid (> 10 mg/kg bw day).

## 4.7.5 Summary and discussion of repeated dose toxicity findings relevant for classification according to DSD

Though medium chain fatty acids (including C8, C9, C10) were applied as repeated dose up to 10 000 mg/kg bw day no systemic LOAEL can be derived from the toxicological studies.

## 4.7.6 Comparison with criteria of repeated dose toxicity findings relevant for classification according to DSD

See chapter 4.7.5. In the toxicological repeated dose studies no adverse effects were observed.

## 4.7.7 Conclusions on classification and labelling of repeated dose toxicity findings relevant for classification according to DSD

No classification necessary, see chapter 4.7.5.

## 4.8 Specific target organ toxicity (CLP Regulation) – repeated exposure (STOT RE)

No classification necessary, see chapter 4.7.5.

## 4.9 Germ cell mutagenicity (Mutagenicity)

### 4.9.1 Non-human information

#### 4.9.1.1 In vitro data

See chapter 4.9. Decanoic acid acid did not induce genotoxicity in the standard bacterial mutation test, the in vitro cytogenicity test or the in vitro gene mutation test, neither with nor without metabolic activation by S9 mix.

The same is true for Octanoic acid with the exception of the in vitro gene mutation test that resulted reproducibly positive at a dose of 10 mM + S9. All other doses were negative.

Considering all the negative genotoxicity results for Octanoic acid and for Decanoic acid and considering the absence of structural alerts of the active substances and the known impurities as well as all arguments listed in chapter 4.7.4. (bullet points) the overall conclusion is that neither Decanoic acid nor Octanoic acid are genotoxic. The positive results are considered to be rather related to cytotoxicity.

Test system	organism/	concentrations	Substance tested	Result		Remark	Reference
Guideline	strain(s)	range)	tested	+ \$9	- S9	cytotoxicity (MI= Mitotic Index in % of control) and other	
Bacterial gene mutation, OECD 471	S. typhimurium: TA 1535, TA 1537, TA 98, TA 100 E. coli: WP2 uvrA	62 – 5000 μg/plate	Decanoic acid	Neg.	Neg.	slightly reduced growth at 1666 and 5000 µg/plate (+S9; - S9)	Van Ommen 1999a; Doc III A6.6.1/1
Bacterial gene mutation, OECD 471	S. typhimurium: TA 1535, TA 1537, TA 98, TA 100 E. coli: WP2 uvrA	62 – 5000 μg/plate	Octanoic acid	Neg.	Neg.	reduced growth above 1500 µg/plate (+S9; - S9)	Van Ommen 1999b; Doc III A6.6.1/02
Cytogenetic test OECD 473	Chinese hamster Ovary K-1 line	5 – 500 µg/ml	Decanoic acid	Neg.	Neg.	Test 1: 200 µg/mL +S9 (MI= 48% ) 50 µg/mL +S9 (MI=80%) 300 µg/mL -S9 (MI=48% ) 100 µg/mL -S9 (MI=83% ) Test 2: 350 µg/mL +S9 (MI=50% ) 200 µg/mL -S9 (MI=80% ) 50 µg/mL -S9 (MI=47%) 10 µg/mL -S9 (MI=82%)	De Vogel 1999a;Doc III A6.6.2/1

Table 18: Summary of genotoxicity for Octanoic acid and Decanoic acid

Cytogenetic test OECD 473	Chinese hamster Ovary K-1 line	25- 1200 μg/ml	Octanoic acid	Neg.	Neg.	Test 1: 200 μg/mL +S9 (MI=48%) 50 μg/mL +S9 (MI=80%) 300 μg/mL -S9 (MI=48%) 100 μg/mL -S9 (MI=98%) Test 2: 350 μg/mL +S9 (MI=50%) 200 μg/mL +S9 (MI=80%) 50 μg/mL -S9 (MI=47%) 10 μg/mL -S9 (MI=82%)	De Vogel 1999b;Doc III A6.6.2/2
Gene mutation in mammalian cells OECD 476	Mouse lymphoma L5178Y cells	0.2 – 10 mM	Decanoic acid	Neg.	Neg.	Single positive response in presence of S9 at 2.2 mM. Effect not dose related and not reproducible. relative cell suspension growth < 10% of control with concentrations ≥3.4 mM	Steenwinkel 1999a; Doc III-A6.6.3/1
Gene mutation in mammalian cells OECD 476	Mouse lymphoma L5178Y cells	0.4 – 10 mM	Octanoic acid	Pos.	Neg.	Reproducible positive response at 10mM + S9 with relative total growth of 35% and pH of 6.9 considered to result from cytotoxicity.	Steenwinkel 1999b; Doc III-A6.6.3/2

Table 18: Summary of genotoxicity for Octanoic acid and Decanoic acid (continued)

### 4.9.1.2 In vivo data

Furthermore within the draft assessment report for fatty acids (C7-C20) prepared by RMS Ireland in the context of 91/414/EEC reference is also given to a negative in vivo mammalian bone marrow chromosome aberration test in Chinese hamsters (Renner 1986, published). The RMS-AT did not independently assess this reference since the available information (see also chapter 4.7. - bullet points) seems sufficient also without this reference.

## 4.9.2 Human information

Detailed knowledge is available on the metabolic pathways that are similar for all fatty acids: complete catabolism for energy supply or conversion to fat suitable for storage (see chapter 4.1). Decanoic acid and Octanoic acid are linear saturated fatty acids and they as well as other similar fatty acids are ubiquitous in nature: Decanoic acid and Octanoic acid are naturally present in many types of food in its free form or as triglyceride (see Gubler 2006, Ref A 6/05). Uptake as natural food source from cheese or coconut oil may be estimated to be significantly above 20 mg/ person day (=estimation from average Swiss cheese consumption; 178 mg decanoic acid and 200 mg octanoic acid and 750 mg octanoic acid per person and day = estimation from 100 g sheep cheese; see Document III-A 6.5.1 and 2). The latter four estimates are in the range of the proposed AEL. The daily human uptake of total fatty acids as food contents may be estimated - e.g. according to Henderson et al 2003 and Ruston et al. 2006 in the range of 900 mg/kg bw day (see Doc II-A 3.1). This may further support the high Acceptable Exposure Level (AEL) for Decanoic acid and Octanoic acid (> 10 mg/kg bw day).

## 4.9.3 Other relevant information

-

#### 4.9.4 Summary and discussion of mutagenicity

Decanoic acid did not induce genotoxicity in the standard bacterial mutation test, the in vitro cytogenicity test or the in vitro gene mutation test, neither with nor without metabolic activation by S9 mix.

The same is true for Octanoic acid with the exception of the in vitro gene mutation test that resulted reproducibly positive at a dose of 10 mM +S9. However actual ICH guidelines for genotoxicity testing propose to reduce the maximum dose within in vitro genotoxicity tests from 10 mM to 1 mM. This is supported by scientific data showing that by reducing the top concentration level to 1mM the number of substances being positive in the in vitro genotoxicity tests but negative in the carcinogenicity studies can be substantially reduced without reducing the sensitivity of the in vitro method (no increase of false negatives): Parry et al. 2010. Mutagenesis 25/6, 531-538; Kirkland et Fowler 2010. Mutagenesis 25/6, 539-553. In addition it is acknowledged that all other doses were negative and also the studies carried out with the structurally strongly related substance decanoic acid were negative.

The results from the in vitro chromosomal aberration test with decanoic acid may be considered borderline for the two highest doses of 300 and 500  $\mu$ g/mL: at both doses 5 of 200 cells (2.5%) with aberrations were observed as compared to 0 of 200 cells in the negative control. The p-values is 0.03 (if one-sided test is considered). However this was not reproduced in the repeated test where a different fixation time was used (This was done since the study author applied a two sided test for the evaluation resulting in a p-value of 0.06 for the first test, that indicated a negative result). In addition these two higher concentrations are again above the concentrations actually recommended by ICH.

Considering all the negative genotoxicity results for Octanoic acid and for Decanoic acid and considering the absence of structural alerts of the active substances and the known impurities as well as all arguments listed in chapter 4.7 (bullet points) the overall conclusion is that neither Decanoic acid nor Octanoic acid are genotoxic

#### 4.9.5 Comparison with criteria

See chapter 4.9.4.

## 4.9.6 Conclusions on classification and labelling

No classification necessary, see chapter 4.9.4.

#### 4.10 Carcinogenicity

#### 4.10.1 Non-human information

Within the 28 day gavage study with Nonanoic acid hyperplasia of the squamous epithelium of the forestomach was observed. However the effect is not considered to be of relevance for human cancer risk assessment. This conclusion is supported by the absence of genotoxic effects, the high doses applied (1000 mg/kg bw day) for achieving the hyperplasia and considering the nature of the active substance, a medium chain saturated fatty acid and the knowledge about kinetics and metabolism of fatty acids (see chapter 4.1). Clearly long term irritation is stimulating cell replication and presents as such a promoting effect that is increasing cancer risk, but such tumour promoting effects without tumour inducing effects are not warrant to

classification. The same considerations are valid for the evaluation with regard to the dermal or inhalation exposure routes.

Therefore the conduct of a further carcinogenicity study was considered not to be necessary, no new toxicological information is expected (see also bullet points in chapter 4.7.)

Furthermore as additional information an EPA study summary is available for a dermal repeated dose study with Nonanoic acid (Barkley 1985; The applicant did not submit a letter of access). One control group (untreated), one vehicle control group (50 mg of mineral oil), one test substance group (50 mg of undiluted Nonanoic acid) and one positive control group (50 mg of a 0.05% solution of benzo(a)pyrene in mineral oil), each group consisting of 50 mice received the treatment twice a week for 80 weeks. At termination, a complete gross necropsy was performed and histopathological examinations of all tissues from all mice were conducted. No treatment-related clinical signs of toxicity were reported. Mean weight of mice treated with Nonanoic acid was similar to that of the untreated controls. No treatment-related non-neoplastic or neoplastic lesions were reported. No skin tumors were seen in the positive control group. The fact that no clinical signs and no lesions were reported with undiluted application of the medium chain fatty acid seems to be in contradiction with the strong irritant properties reported in the acute and repeated dose studies, however without the full study report this aspect cannot be further discussed.

Furthermore within the draft assessment report for fatty acids (C7-C20) prepared by RMS Ireland in the context of 91/414/EEC reference is also given to a comparative 2-year rat gavage study with corn oil, safflower oil and tricaprlyin in rats (GLP study). All substances caused in increase in pancreatic tumors and a decrease in mononuclear cell leukaemia. Male animals in the corn oil group also showed a distinct dose related increase in fatty liver. These were all considered as normal, well-known responses of male F344 rats to high fat diets. Doses above 2000 mg/kg bw were applied in this test. Clearly also RMS Ireland does not propose classification for carcinogenicity. The RMS-AT did not independently assess this reference since the available information (see also chapter 4.7. - bullet points) seems sufficient also without this reference.

## 4.10.2 Human information

See chapter 4.9.2.

## 4.10.3 Summary and discussion of carcinogenicity

Information on human dietary uptake of fatty acids as well as knowledge of human metabolism, negative genotoxicity studies as well as absence of any toxicological alerts from available repeated dose studies with medium chain triglycerides as well as nonanoic acid allow the conclusion that there is no concern for carcinogenicity

## 4.10.4 Comparison with criteria

See chapter 4.10.3.

## 4.10.5 Conclusions on classification and labelling

No classification for carcinogenicity is necessary.

## 4.11 Toxicity for reproduction

## 4.11.1 Effects on fertility

**Harkins et Sarett 1968** (see Doc III-A 6.4.1.1/02) published a nutritional evaluation of a medium chain triglyceride (MCT) preparation. A casein diet, containing 18.5% MCT and 2.5% safflower oil, the latter to supply essential fatty acids, was compared with similar diets containing conventional dietary fats. The MCT contained about 51% octanoic acid and 35%

Decanoic arid resulting in an Octanoic acid dietary dose of about 4700 mg/kg bw day and a Decanoic acid dietary dose of about 3200 mg/kg bw day. Data obtained in a 47-week study showed that the MCT diet supported normal growth and development. The MCT diet supported normal reproduction, as indicated by litter size and number. However weight gain of F1 rats was highest with the oleo oil diet, lower with the MCT diet but lowest with the low-fat diet. Furthermore mortality was 7% or less in all groups except for the group receiving MCT for two generations (P and F1, 22%) and the group receiving low-fat diet in the Pgeneration and MCT in the F1 generation (20%). In contrast weight gain of the F2 generation fed on MCT for 2 generations was higher compared to all other groups. Determination of the amount of milk secreted by the mothers of each subgroup suggested that this may have affected weight gain and mortality: F1 generation rats that received the MCT diet in the P and F1 generation secreted a lower volume of milk with a lower level of fat compared to rats receiving an oleo oil diet. Furthermore it is reported that differences in weight gain is related in part to food intake since caloric efficiency were similar on all three diets. Consequently it may be concluded that the adverse effects observed stem from nutritional imbalances with high dose applications rather than from substance specific toxic mechanisms. Accordingly for Decanoic acid and Octanoic acid as medium chain triglycerides an overall NOAEL of  $\geq$  8000 mg/kg bw day is apparent in this study.

Taking furthermore into consideration the arguments listed in chapter 4.7 (bullet points) there is no concern for reproductive toxicity.

Route of exposure	Testtype Method Guideline	Species Strain Sex no/group	Exposure Period	Doses	NO(A)EL Parental; F1; F2 (male and female)	Reference
Oral (feeding of medium-chain triglycerides containing 35% Decanoic acid and 51% Octanoic acid)	47 weeks	Rat, McCollum -Wisconsin	From 3 weeks prior to mating throughout the whole study	40% of daily calories in food supplied by MCT (assuming default food conversion factor between 0.1 and 0.05 equivalent to ca. 3 g/kg bw/day decanoic acid)	≥ 8000 mg/kg bw/day	Harkins, 1968; A6.8.2 and A6.4.1.1/ 02

Table 20: Summary of decanoic acid information of fertility

## 4.11.1.1 Non-human information

See chapter 4.11.1.

## 4.11.1.2 Human information

See chapter 4.9.2.

## 4.11.2 Developmental toxicity

No specific teratogenicity study has been performed, but the following references were provided:

Scott et al. 1994 (A6.8.1/01 in reference list) reports that Octanoic acid was applied as single dose of 3228 mg/kg bw on day 12 of gestation, rats were killed and analysed on day 20 of gestation. No teratogenic effects were reported. The difference between octanoic acid and teratogenic valporic acid (= 2-propyl pentanoic acid) is explained to be related to the plasma level and half live that are magnitudes lower for octantanoic acid.

Mei-Jen Liu and Gary M. Pollack 1993 (A6.8.1/02 in reference list) reports the toxicokinetics and metabolism of valporic acid, cyclohexanecarboxylic acid, 1-methyl-1-cyclohexanecarboxylic acid and octanoic acid in Sprague-Dawley rats (4 animals per dose, 3 doses, intravenous application, analysis in serum and urine). It was shown that octanoic acid differs significantly from the other substances: Plasma half lives are very short (<5 minutes), no enterohepatic circulation and no recovery in urine, neither as parental substance nor as glucoronide-metabolites. This finding is explained by the fact that it is a naturally occurring substrate with a linear structure that allows easy mitochondrial β-oxidation.

These data together with the considerations listed in chapter 4.7 (bullet points) sufficiently support that there is no concern for developmental toxicity of Decanoic acid.

It may also be acknowledged that a developmental toxicity study with Nonanoic acid was submitted in the context of the BPD 98/8/EC Annex I inclusion procedure. The study is owned by the respective applicant W. Neudorff GmbH KG and the data are protected. However since the data requirement for the evaluation of developmental toxicity is fulfilled with the references provided above and the study is not used to the advantage of the applicant of Decanoic and Octanoic acid (Fatty Acid Consortium) it may be cited and discussed also for the evaluation of Decanoic acid and Octanoic acid: In a developmental toxicity study, pregnant CD rats were administered Nonanoic acid in corn oil by oral intubation at 0 and 1500 mg/kg bw/day during days 6 through 15 of gestation. Treatment had no adverse effect on clinical signs, body weights, body weight gain, or food/water consumption and no maternal gross pathological effects were found in the thoracic, abdominal and pelvic viscera. Nonanoic acid did not cause any fetal toxicity; the mean numbers of viable foetuses, early or late resorptions, implantation sites, corpora lutea, pre- and post-implantation losses, sex ratios and fetal body weights in the treated group were comparable to those of the control group. No development toxicity was seen; Nonanoic acid did not increase the external, visceral, or skeletal malformations or variations in any of the foetuses. The NOAEL for maternal and developmental toxicity was 1500 mg/kg bw/day.

## 4.11.2.1 Non-human information

See chapter 4.9.2.

## 4.11.2.2 Human information

See chapter 4.11.2.

## 4.11.3 Other relevant information

See chapter 4.11.1 and 4.11.2.

#### 4.11.4 Summary and discussion of reproductive toxicity

Data for potential effects on fertility are available with medium chain fatty acid triglycerids. Data for potential effects on the development are available for octanoic acid and for nonanoic acid. None of these data indicate a concern for reproductive toxicity. However this is also not to be expected given the knowledge on metabolism in humans and daily exposure to fat as nutrient.

### 4.11.5 Comparison with criteria

See above.

## 4.11.6 Conclusions on classification and labelling

No classification for reproductive toxicity is necessary.

#### 4.12 Other effects

#### 4.12.1 Non-human information

#### 4.12.1.1 Neurotoxicity

Neither the available studies and publications nor general considerations of structure and metabolism indicate a concern for neurotoxicity of Decanoic acid or Octanoic acid with oral, dermal or inhalation exposure (see also chapter 4.7.4., bullet points)

#### 4.12.1.2 Immunotoxicity

No Data available.

## 4.12.1.3 Specific investigations: other studies

No Data available.

## 4.12.2 Human information

No Data available.

#### 4.12.3 Summary and discussion

See discussion above.

#### 4.12.4 Comparison with criteria

See discussion above.

## 4.12.5 Conclusions on classification and labelling

No classification necessary.

## 5 ENVIRONMENTAL HAZARD ASSESSMENT

Preliminary note: The references to key studies are highlighted bold throughout this chapter.

#### 5.1 Degradation

#### 5.1.1 Stability

#### Hydrolysis

A justification for non-submission of data (**Doc. III-A 7.1.1.1**) was submitted stating that Decanoic acid does not contain any functional group or reactive centre, which can be hydrolysed by nucleofilic  $OH^-$  ions (at high pH values) or by electrophilic  $H_2O^+$  ions (at low pH values). (See also **Study A 3/02D and A 3/16, Doc. III-A 3**). Therefore, Decanoic acid will not be able to react with water and will not be hydrolysed in water at the given pH values.

Conclusion:

Hydrolysis is not relevant for abiotic degradation of Decanoic acid.

#### Photolysis in water

Aqueous photolysis can occur for substances which have UV/visible light absorption maxima in the range of 290 to 800 nm. A justification for non submission of data (**Doc. III-A 7.1.1.1.2**) was submitted stating that Decanoic acid does not contain any functional group or reactive centre, which display chromophore properties at wavelengths above 290 nm. (See also **Study A 3/01D, Doc. III-A 3**). Therefore, photolytic degradation in water is excluded.

Conclusion:

Photolysis is not relevant for abiotic degradation of Decanoic acid.

#### Phototransformation in air

The photochemical degradation of Decanoic acid in air was estimated using the model AOPWIN (version 1.92, Epi Suite, Syracuse Research Corporation, see **Doc. III-A 7.3.1**).

The specific degradation rate constant of Decanoic acid with OH-radicals was estimated to be  $k_{OH} = 11.176 \text{ x}$ 10<sup>-12</sup> cm<sup>3</sup>/molecule/s, mainly due to hydrogen abstraction (ca. 95%) and reaction with the hydroxyl-group (ca. 5%). Other mechanisms do not contribute to hydroxyl radical estimations. By relating  $k_{OH}$  to the average OH-radical concentration in the atmosphere c(OH)<sub>air</sub>, the pseudo-first order rate constant for degradation in air k <sub>deg, air</sub> can be derived:

 $k_{deg, air} = k_{OH} x c(OH)_{air} x 24 x 3600 [d^{-1}]$ 

According to the TGD on Risk Assessment,  $c(OH)_{air} = 5 \times 10^5$  molecules x cm<sup>-3</sup>, which leads to

 $k_{deg, air} = 1.448 d^{-1}$ ,  $T_{1/2} = 34.5 h$  (TGD)

Conclusion:

The half-life of Decanoic acid is estimated to be 34.5 h. Based on this result an accumulation of Decanoic acid in air is not to be expected.

Substances which are contributing to degrading air quality (visibility, effects on human health, bad smell, effects on plants), global warming, ozone depletion in the atmosphere and ozone formation in the troposphere, acidification and/or long range transport, have the potential to display adverse abiotic effects on the atmospheric environment.

On the basis of its physical and chemical properties, as e.g. absence of absorption bands in the so-called atmospheric window (800-1200 nm; **Doc. III-A 3, Study A 3/01D**), short atmospheric lifetime (**Doc. III-A 7.3.1**), absence of Cl, F, N or S substituents in the molecule (**Doc. III-A 2**), Decanoic acid is not expected to display adverse abiotic effects on the atmospheric environment.

#### 5.1.2 Biodegradation

The oxidative degradation of fatty acids is a universal biochemical capacity among living organisms. Within cells, fatty acid oxidation occurs principally in the mitochondria; β-oxidation is the normal mechanism, in which two-carbon units are sequentially removed beginning from the carboxyl-terminal end (Orten and Neuhaus 1975). A detailed chapter on the enzymology of beta-oxidation is written by Zubay 1983.

Consequently, straight-chain fatty acids with e.g. 9 carbons are oxidized by the normal ß-oxidation sequence and give rise to 3 acetyl-CoAs and 1 propionyl-CoA.

The propionyl-CoA is converted to succinyl-CoA. Succinyl-CoA can be further metabolized in the tricarboxylic acid cycle. As a result of the in details complicated degradation steps of fatty acids the final products are  $CO_2$  and water. No other products than these ones are formed.

#### 5.1.2.1 Biodegradation estimation

No data available

#### 5.1.2.2 Screening tests

The biodegradation of Decanoic acid was investigated in a Manometric responsery test (Study A 7.1.1.2.1/02, Doc. III-A 7.1.1.2.1) according to OECD guideline 301 F. The biochemical oxygen demand of Decanoic acid in the test media significantly increased starting at day 1. After 5 days of exposure the mean biodegradation amounted to 62%. At the end of the 10-day window on day 11, 79% and 80% biodegradation were found. At the end of the 28-day exposure period a mean degradation rate of 92% was calculated. The percentage biodegradation exceeded 60% after 28 days and within the 10-day window.

Further information:

Additionally literature was submitted (Study A 7.1.1.2.1/01 "Fragrances and Biodegradation, Göteborgs Stad Miljö, ISSN 1401-2448 ISRN GBG-M-R—05/05—SE") including a list of organic acids (e.g. Decanoic acid) which were found to be readily biodegradable. The report comes to the conclusion that saturated alkane carboxylic acids are readily biodegradable at least up to C18. Both statements are in line with the findings from the degradation study presented here and with the explanation of the metabolism of fatty acids (see above).

Conclusion:

Decanoic acid was found to be "readily biodegradable".

Therefore the justification for non submission of data for inherent biodegradability (**Doc. III-A7.1.1.2.2**) was accepted and no further studies on biodegradation (simulation) tests have been asked for.

However, in the risk assessment for PT 4 the  $DT_{50}$  soil from Nonanoic acid of 1.1 days at 20°C, corresponding to 2.1 days at 12°C (Draft Competent Authority Report, Document I, Nonanoic acid, Product Type 19, 2008) was used in order to refine the risk characterisation for the soil compartment.

Guideline /	Test	Test	Inoculum			Addi-	Test	Degradation		Reference
Test method	type	para- meter	Туре	Concen tration	Adapt ation	tional sub- strate	substance concentr.	Incu- bation period	Degree [%]	
EEC C.4-D, OECD 301- F / Manometric respirometr y test	read y	Oxygen demand (measur ement of pressure drop)	Aerobic active- ated sludge	30 mg suspend -ded solids/L	No	No	100 mg Decanoic acid/L	11 days (10 day window) 28 days	79-80% 91-92%	Study A 7.1.1.2.1/ 02 Doc. III-A 7.1.1.2.1

Table 21a: Biodegradability, screening tests

<sup>1</sup>Test on *inherent* or *ready* biodegradability according to OECD criteria

## 5.1.2.3 Simulation tests

No data available.

## 5.1.3 Summary and discussion of degradation

Decanoic acid is readily biodegradable (92% at day 28; pass level reached at day 5). The principal way of degradation of fatty acids under aerobic conditions is the microbial shortening by C2 pieces ( $\beta$ -oxidation of fatty acids). In addition the DT<sub>50</sub> soil from Nonanoic acid of 2.1 days at 12°C (Draft Competent Authority Report, Document I, Nonanoic acid, Product Type 19, 2008) was used for read across in order to refine the risk characterisation for the soil compartment of PT 4.

Hydrolysis can be excluded by its structure, since Decanoic acid does not contain any functional group or reactive centre, which can be hydrolysed by nucleophilic  $OH^-$  ions (at high pH values) or by electrophilic  $H_2O^+$  ions (at low pH values).

Photolytic degradation in water is excluded for Decanoic acid, as it does not contain any functional group or reactive centre which displays chromophore properties at wavelengths above 290 nm.

An estimation of photochemical degradation of Decanoic acid in air according to TGD resulted in a half-life of 34.5h (k <sub>deg, air</sub> =  $1.448 \text{ d}^{-1}$ ; c(OH)<sub>air</sub> =  $5 \times 10^5$  molecules/cm<sup>3</sup>). Based on this result an accumulation of Decanoic acid in air is not expected.

## 5.2 Environmental distribution

## 5.2.1 Adsorption/Desorption

In a study according to OECD guideline 106 the adsorption characteristics of Decanoic acid were investigated (Study A 7.1.3/01, Doc. III-A 7.1.3).

Initially a preliminary test was conducted using soil I and II (table 21b) with three soil-to-solution ratios (1/1, 1/5 and 1/25). After 2, 5, 24 and 48 h of incubation no test substance was detected in the supernatants, except after 5h of incubation at the 1/5 ratio. Since strong adsorption of the test item to soil and complexation with Ca-ions were excluded, it was assumed that the test item degraded under the test conditions.

In a second step a screening test was performed using five soils sterilised by gamma-irradiation, a soil-tosolution ratio of 1/5 and an adsorption time of 4h. The test item disappeared completely from the supernatants, except for soil III. In the steril control (without soil), the test item was recovered. The soils were extracted with acetonitrile solution. Virtually no test item could be detected in the extract solutions by LC/MS analysis. Extracts from untreated soil (blank extracts) were spiked with Decanoic acid and analysed by LC/MS. Again no test item could be detected. The same blank extracts sterilised by autoclaving showed complete recovery of the test item which confirms the microbial degradation of Decanoic acid in the tested soils..

Higher concentrations of Decanoic acid were measured after sterilisation of the soils at 120°C, but degradation could not be avoided for all samples. Desorption was performed for the same soils, but no test substance was detected in the desorption solutions.

Conclusion:

An adsorption equilibrium could not be reached, since Decanoic acid rapidly degraded despite of soil sterilisation. For above-mentioned reasons no  $K_{oc}$  value could be calculated. At the same time the result shows that there is negligible likelihood for leakage of Decanoic acid to groundwater due to rapid degradation.

In the risk characterisation a default  $K_{\rm oc}$  value for the non-ionised form of Decanoic acid of 264 L/kg (calculated via EUSES) was used.

Guideline / Test method	Soil	Substance	Koc <sub>ads</sub>	Koc <sub>des</sub>	Reference
OECD 106 / Adsorption – Desorption Using a Batch Equilibrium Method	Soil I: sandy loam Soil II: loam Soil III: sandy clay Soil IV: silty loam Soil V: silty clay	Decanoic acid	n.a.	n.a.	Study A 7.1.3/01, Doc. III-A 7.1.3

Table 21b: Adsorption onto / desorption from soils

## 5.2.2 Volatilisation

Table 21c: Vapour pressure

Property	Purity/Specification	Results	Reference
Vapour pressure	100%	2.17 x 10-4 Pa (25°C) 2.096 x 10-4 Pa (20°C)	Doc. III-A 3; Study A3/01D
Henry's Law Constant	n.a.	0.472 Pa x m <sup>3</sup> x mol <sup>-1</sup> (calculated according to HENRYWIN 3.10)	Doc. III-A 3; Study A3/04

The transfer of a substance from the aqueous phase to the gas phase is estimated by means of its Henry's Law constant.

K air-water = (HENRY) / (R\*Temp) =  $1.9*10^{-4}$ With HENRY [Pa \* m<sup>3</sup> \*mol<sup>-1</sup>], R = 8.314 Pa \* m<sup>3</sup> -mol<sup>-1</sup>\*K<sup>-1</sup>; Temp [K]

#### 5.2.3 Distribution modelling

No data available.

#### 5.3 Aquatic Bioaccumulation

#### 5.3.1 Aquatic bioaccumulation

#### 5.3.1.1 Bioaccumulation estimation

The BCF is calculated with the program of EPI Suite and according to formula 74 of the TGD for completeness. The calculation of the BCF with the program of EPI Suite results in a BCF value of 1262 when a biotransformation rate of zero is estimated. If biotransformation is taken into account, the BCF ranges from 395 to 404. This is in line with the BCF calculated according to the TGD (BCF=598, see below). So a BCF of 598 is applied.

Table 22: Estimations on aquatic bioconcentration

Basis for estimation	log P <sub>OW</sub>	Estimated BCF for Decanoic acid	Reference
Calculation	4.09	The log BCF-value can be calculated using the log $P_{ow}$ value log BCF=0.85 x log $P_{ow}$ -0.7 Based on a calculated log $P_{ow}$ of 4.09 the log BCF <sub>fish</sub> can be calculated as: log BCF <sub>fish</sub> =0.85 x 4.09- 0.70 = 2.776 BCF <sub>fish</sub> =597.72	TGD on Risk Assessment

The calculated  $BCF_{fish}$  for Decanoic acid is 598.

#### 5.3.1.2 Measured bioaccumulation data

No study on bioconcentration in aquatic organisms is performed.

#### 5.3.2 Summary and discussion of aquatic bioaccumulation

Based on its chemical structure, Decanoic acid is a so called amphiphile molecule. This is a term describing a chemical compound possessing both hydrophilic and lipophilic properties. As a result of having both lipophilic and hydrophilic portions, some amphiphilic compounds may dissolve in water and to some extent in non-polar organic solvents. When placed in an immiscible biphasic system consisting of aqueous and organic solvent, the amphiphilic compound will partition into the two phases. The extent of the hydrophobic and hydrophilic portions determines the extent of partitioning. This is the reason why no experimental log  $P_{ow}$  can be determined for Decanoic acid. Because the substance is completely miscible in Octanol, the Octanol/water coefficient cannot be calculated by the relation of water saturation concentration and Octanol saturation concentration. In the Guidance for the implementation of REACH, Chapter R.7A – Endpoint specific guidance, it is stated that the Shake Flask Method, which is a direct measurement method to estimate data on partition coefficient n-Octanol/water, is not suitable for surface active substances.

According to the TGD "Guidance document on data requirements for active substances and biocidal products" the value should be calculated if a test cannot be performed. Hence data from calculations using equations based on fragment contribution methods are only of limited validity. The validity of such QSAR methods decrease generally as the complexity of the molecule increases. However, as Decanoic acid is a very simple molecule (ten-carbon straight-chain fatty acid  $(C_{10}H_{20}O_2)$ ) the model calculations can be assumed to be a reliable estimate. For comparison, the log  $P_{ow}$  from other fatty acids are mentioned (Octanoic acid 3.03, Nonanoic acid 3.52, both estimated with QSAR methods).

So the calculated  $\log P_{ow}$  can be accepted.

Octanoic acid is surface active. Due to the similar molecular structure, it is expected that Decanoic acid may also be surface active. As surface active molecules could have a potential for bioaccumulation, the testing of the bioaccumulation in an appropriate species of fish might be necessary.

For Decanoic acid, bioaccumulation is not an important issue, because

- Decanoic acid is as rapidly biodegradable
- Decanoic acid is a fatty acid. Fatty acids are ubiquitous available in the environment and important naturally occurring biological molecules, found in all living organisms. They may be regarded as having fundamental roles (i.e. they are the building blocks of structurally important molecules in cellular membranes and also serve as sources of energy for biological systems).
- Decanoic acid is metabolized via β-oxidation. This is quantitatively the most significant pathway for catabolism of fatty acids and results in the final products CO<sub>2</sub> and acetyl-CoA which as such are further metabolized to CO<sub>2</sub> and water (for details of the degradation steps see chapter 4.1 Toxicokinetics, Metabolism and Distribution).

The calculated  $BCF_{fish}$  for Decanoic acid is 598. Based on the facts and arguments given above (the knowledge on metabolism and biological properties of fatty acids) sufficient evidence is given of the non-bio-accumulating properties of Decanoic acid.

## 5.4 Aquatic toxicity

Classification is based on the key studies (results and references highlighted bold).

#### Tables 23: Summary of relevant information on aquatic toxicity

See chapters 5.4.1, 5.4.2, 5.4.3, 5.4.4.

## 5.4.1 Fish

### 5.4.1.1 Short-term toxicity to fish

An older study, not fulfilling the validity criteria, as lacking in details on the actual concentrationes of the test substance and the dissolved oxygen as well is available and presented as supportive reference only (Study A 7.4.1.1/01). As there are consistent results, the read across to the new acute toxicity study in fish with Octanoic acid is supported.

The acute toxicity of Octanoic acid was investigated in zebra fish (*Brachydanio Rerio*) in a semi-static study for 96 hours (Studies A **7.4.1.1/02 O** and A **7.4.1.1/03 O**, Doc. III-A **7.4.1.1**). The NOEC was 22 mg/L as this was the lowest concentration where no effects could be estimated (which corresponds to 26.3 mg/L Decanoic acid). At 46 mg/L abnormal fish could be seen (corresponding to 55 mg/L Decanoic acid). However, no mortalities occur at this test concentration. The calculated  $LC_{50}$  is 68 mg/L (corresponding to 81.2 mg/L Decanoic acid).

Conc. Decanoic acid [g/L] = conc. Octanoic acid [g/L] \* MM Deca [g/mol] / MM Octa [g/mol], where: MM Decanoic acid = 172.27 g/mol and MM Octanoic acid = 144.21 g/mol

For the results given in Decanoic acid on equimolare basis see table 23a below:

Guideline / Test method	Species	Endpoint	<b>Exposure</b> design	e duration	<b>Results in nominal</b> LC <sub>0</sub>	n mg/L, LC <sub>50</sub>	LC <sub>100</sub>	Remarks	Reference
OECD 203 / EC C.1	Zebra fish (Brachydanio rerio)	Mortality	Semi- static	96 h	55*	81.2*	119.4*	Read accross from Octanoic acid	Study A 7.4.1.1/02 O and Study A 7.4.1.1/03 O Doc. III-A 7.4.1.1
DIN 38412/15	Golden orfe (Leuciscus idus)	Mortality	static	48 h	30	95	300	Added as supporting effidence	Study A 7.4.1.1/01

Table 23a: Acute toxicity to fish

\* nominal confirmed

## 5.4.1.2 Long-term toxicity to fish

No data available.

## 5.4.2 Aquatic invertebrates

#### 5.4.2.1 Short-term toxicity to aquatic invertebrates

Acute toxicity of Decanoic acid to daphnids (*Daphnia magna*) was investigated in a semi-static study (Study A **7.4.1.2/01 Doc. III-A 7.4.1.2**). The highest tested nominal concentration causing no mortality after 48 hours was 10 mg/L. The EC<sub>50</sub> was 16 mg /L. For the results see table 23b below:

Table 23b: Acute toxicity to invertebrates

Guideline / Test	Species	Endpoint / Type of test	Exposu	re	Results nomina	in mg /I ll confirr	-, ned	Remarks	Reference
method			design	duration	EC <sub>0</sub>	EC <sub>50</sub>	EC <sub>100</sub>		

OECD 202- I	Daphnia magna	immobilisation / acute	Semi- static	48h	10	16	46	 Study A 7.4.1.2/01 Doc. III-A 7.4.1.2
								111 11 7.4.1.2

## 5.4.2.2 Long-term toxicity to aquatic invertebrates

No data available.

## 5.4.3 Algae and aquatic plants

A static study according to guideline OECD 201 was conducted to estimate the the toxicity of Decanoic acid to the algae *Scenedesmus subspicatus* (Study A 7.4.1.3/01, Doc. III-A 7.4.1.3). The highest initial concentration tested at which the measured parameters do not show a significant inhibition of cell growth rate relative to control values is 0.57 mg/L (NOE<sub>r</sub>C). As the test item decreases during the test period, the results are given in mean measured concentrations (calculated as geometric mean). For the results see table 23c below:

Table 23c: Growth inhibition on algae

Guideline /	Species	Endpoint / Type of	Exposure Results in mg/L mean measured		Remarks	Reference			
Test method		test	design	duration	NOE <sub>r</sub> C	$E_bC_{50}^{1}$	$E_{r}C_{50}^{2}$		
OECD 201 / EC C.3	Scenedes mus subspicatus	Growth and biomass inhibition	static	72 h	0.57	1.16	2	-	Study A 7.4.1.3/01 Doc. III-A 7.4.1.3

<sup>1</sup> calculated from the area under the growth curve;

<sup>2</sup> calculated from growth rate

## 5.4.4 Other aquatic organisms (including sediment)

## Inhibition of microbial activity (aquatic)

The inhibitory effects of Decanoic acid against aquatic micro-organisms were investigated in an activated sludge respiration inhibition test according to OECD guideline 209 (**Study A 7.4.1.4/01, Doc. III-A 7.4.1.4**). In this study the nominal concentrations of 10, 32, 100, 320 and 1000 mg a.s./L were incubated for 3h.

Although Decanoic acid has limited water solubility in unbuffered tap water the test substance was directly mixed into the tap water by ultrasonic treatment for fifteen minutes and intense stirring for 24h to dissolve a maximum amount of test item and/or disperse it as homogeneously as possible. No emulsifier or solvent was used. Down to the lowest test concentration at least part of the test item was not dissolved. Finally the synthetic wastewater (buffered) and the activated sludge were added. It can be assumed that the test item was dissolved during the 3-hour incubation period since the test item was ready biodegradable (10% degradation within the first 24 hours and about 60% degradation after five days of incubation; RCC Study No. A86567 - Decanoic acid: Ready biodegradability in a manometric respirometry test; see Doc. III-A7.1.1.2.1). Furthermore it can be assumed that the test substance concentration was maintained throughout the test at >80% of the initial concentration, as was measured in the acute toxicity tests with daphnia and algae.

This point was also discussed with other member states during the commenting phase of the draft CAR and it was accepted to choose 1000mg/L as NOEC for micro-organisms.

At all tested concentrations Decanoic acid had no inhibitory effect on the respiration rate in comparison to the control, but it enhanced the respiration rates, due to the fact that it serves as a substrate for microorganisms (10 mg a.s./L: +7.9%; 32 mg a.s./L: +13.9%, 100 mg a.s./L: +18.2%; 320 mg a.s./L: +42.3%; 1000 mg a.s./L: +20.8%).

#### Conclusion:

The EC<sub>20</sub>, EC<sub>50</sub> and EC<sub>80</sub> could not be calculated since no inhibition was observed throughout the test. The NOEC was therefore determined with  $\geq$ 1000 mg a.s./L (nominal).

Table 23d	Effects on	microbial	activity	(aquatic)
1 abic 25u.	Lifects on	microolar	activity	(aqualle)

Guideline /	Species /	Endpoint /	Endpoint / Exposure		Results		Re-	Reference
Test method	Inoculum	Type of test	design	duration	NOEC	EC <sub>20</sub> , EC <sub>50</sub> and EC <sub>80</sub>	marks	
OECD 209 / Activated Sludge, Respiration Inhibition Test	Aerobic activated sludge	Oxygen measurement / Respiration inhibition	static with aeration and stirring	3h	>1000 mg a.s./L (nominal) no inhibition observed	n.a. no inhibition observed		Study A 7.4.1.4/01 Doc. III-A 7.4.1.4

## 5.5 Comparison with criteria for environmental hazards (sections 5.1 – 5.4)

## CLP:

#### Aquatic Acute 1:

Aquatic acute toxicity:  $L(E)C_{50}$  values for all three trophic levels (fish: read across from Octanoic acid (C8 fatty acid)) >1 mg/L;

Lowest L(E)C<sub>50</sub> value:  $E_rC_{50}$  (algae) =2 mg/L

 $\rightarrow$  No classification

#### Studies used:

- Doc. III-A 7.4.1.1: Bätscher R. (2006), OECD 203, Acute toxicity to Zebra fish (*Brachydanio rerio*) in a 96-hour semi-static test and first amendment to study plan -> LC<sub>50</sub> (fish, converted to Decanoic acid) =81.2 mg/L
- Doc. III-A 7.4.1.2: Bätscher R. (2006), OECD 202, Decanoic acid: Acute Toxicity to Daphnia manga in a 48-hour immobilization test -> EC<sub>50</sub> (crustacea) =16 mg/L
- Doc. III-A 7.4.1.3: Bätscher R. (2008), OECD 201, Decanoic acid: Toxicity to *Scenedesmus* subspicatus in a 72-hour algal growth inhibition test ->  $E_rC_{50}$  (algae) =2 mg/L

#### **Aquatic Chronic Categories:**

Decanoic acid is rapidly biodegradable, adequate chronic toxicity data are only available for algae, NOE<sub>r</sub>C =0.57 mg/L, which lead to a classification with Aquatic Chronic 3.

For fish (read across from Octanoic acid (C8 fatty acid)) and crustacea only short term toxicity values in the range of 10 - 100 mg/L are available, which in combination with a calculated log P<sub>ow</sub> of 4.09 lead to classification with Aquatic Chronic 3 although the substance is readily biodegradable. Since only experimentally determined BCF values are relevant for classification, the calculated BCF for fish was not considered.

#### **Aquatic Chronic 1:**

➔ No classification

#### **Aquatic Chronic 2:**

 $\rightarrow$  No classification

#### **Aquatic Chronic 3:**

→ Classification with Aquatic Chronic 3

#### Studies used:

- Doc. III-A 7.1.1.2.1: Seyfried B. (2006), OECD 301 F Decanoic acid: Ready biodegradability in a
  manomeatric respirometric respirometry test -> 91-92% degradation in 28 days
- Doc. III-A 3: Partition coefficient of Decanoic acid, (Estimation with EPI Suite) -> log P<sub>ow</sub>=4.09
- Calculation according to TGD on Risk Assessment -> BCF fish. calculated =597.72
- Doc. III-A 7.4.1.1: Bätscher R. (2006), OECD 203, Acute toxicity to Zebra fish (*Brachydanio rerio*) in a 96-hour semi-static test and first amendment to study plan -> LC<sub>50</sub> (fish, converted to Decanoic acid) =81.2 mg/L
- Doc. III-A 7.4.1.2: Bätscher R. (2006), OECD 202, Decanoic acid: Acute Toxicity to *Daphnia* manga in a 48-hour immobilization test -> EC<sub>50</sub> (crustacea) =16 mg/L
- Doc. III-A 7.4.1.3: Bätscher R. (2008), OECD 201, Decanoic acid: Toxicity to *Scenedesmus* subspicatus in a 72-hour algal growth inhibition test -> NOE<sub>r</sub>C<sub>50</sub> (algae) =0.57 mg/L

#### DSD:

Decanoic acid is rapidly biodegradable, it has a log  $P_{ow}$  of 4.09 and a calculated BCF<sub>fish</sub> of 597.72. Acute aquatic toxicity values are available for all three trophic levels (fish: read across with Octanoic acid (C8 fatty acid)), L(E)C<sub>50</sub> values are all between 1 - 100 mg/L. Lowest value is the E<sub>r</sub>C<sub>50</sub> value from algae with 2 mg/L.

#### R50/53:

➔ No classification

#### R50:

➔ No classification

#### R51/53:

The lowest short term value is the  $E_rC_{50}$  from algae with 2 mg/L, which leads to a classification with R51 and in combination with a log  $P_{ow}$  of 4.09 to a classification with N; R51/53, although the substance is rapidly biodegradable. Since only experimentally determined BCF values are relevant for classification, the calculated BCF for fish was not considered.

→ Classification with R51/53

#### R52/53:

➔ No classification

#### Studies used:

- Doc. III-A 7.1.1.2.1: Seyfried B. (2006), OECD 301 F Decanoic acid: Ready biodegradability in a manomeatric respirometric respirometry test -> 91-92% degradation in 28 days
- Doc. III-A 3: Partition coefficient of Decanoic acid, (Estimation with EPI Suite) -> log P<sub>ow</sub>=4.09
- Calculation according to TGD on Risk Assessment -> BCF fish. calculated =597.72
- Doc. III-A 7.4.1.1: Bätscher R. (2006), OECD 203, Acute toxicity to Zebra fish (*Brachydanio rerio*) in a 96-hour semi-static test and first amendment to study plan -> LC<sub>50</sub> (fish, converted to Decanoic acid) =81.2 mg/L
- Doc. III-A 7.4.1.2: Bätscher R. (2006), OECD 202, Decanoic acid: Acute Toxicity to *Daphnia* manga in a 48-hour immobilization test -> EC<sub>50</sub> (crustacea) =16 mg/L
- Doc. III-A 7.4.1.3: Bätscher R. (2008), OECD 201, Decanoic acid: Toxicity to *Scenedesmus* subspicatus in a 72-hour algal growth inhibition test ->  $E_rC_{50}$  (algae) =2 mg/L

# 5.6 Conclusions on classification and labelling for environmental hazards (sections 5.1 – 5.4)

## <u>CLP:</u>

Proposed classification and labelling according to Reg. (EU) No 1272/2008, Annex VI, Table 3.1 and Reg. (EU) No 286/2011

Class	sification and	Labelling	Justification		
<b>GHS Pictograms</b>		-	No classification for acute toxicity is		
Signal words		-	proposed since for all three tropic levels $L(E)C_{50}$ values > 1mg/L are available.		
Classification		Aquatic Chronic 3	Chronic Toxicity: Rapidly degradable		
Hazard statements		H412: Harmful to aquatic life with long lasting effects	substance for which adequate chronic toxicity data are available for algae. Lowest chronic value is the geometric mean NOE <sub>r</sub> Cs from algae with 0.57 mg/L		
General Grevention		-			
		P273: Avoid release to the environment	> Aquatic Chronic 3.		

Response	-	For fish and crustacea $L(E)C_{50}$ values in the range from $10 - 100$ mg/L are available, which in combination with ready biodegradability and a log P <sub>ow</sub> of 4.09 also lead to classification with Aquatic Chronic 3. The caldulated BCF <sub>fish</sub> value of 597.72 was not considered for the classification proposal.
Storage	-	
Disposal	P501: Dispose of contents/container in accordance with local/regional/national/ international regulations (to be specified).	

## DSD:

Proposed classification and labelling according to Reg. (EU) No 1272/2008, Annex VI, Table 3.2

## **Classification and Labelling**: N

R51/53 S61

**Justification:** Decanoic acid is readily biodegradable. The log  $P_{ow}$  is given with 4.09 and a calculated BCF<sub>fish</sub> with 597.72. L(E)C<sub>50</sub> values are available for all three trophic levels in the range from 1 to 100 mg/L. The lowest  $E_rC_{50}$  from algae is 2 mg/L, which in combination with a log  $P_{ow}$  of 4.09 leads to a classification with N; R51/53 and S61. The calculated BCF value was not taken into account for classification, since only experimentally derived BCF values are considered relevant for classification.

## **6 OTHER INFORMATION**

Not available

## 7 **REFERENCES**

Section no/ reference no	Year	Title Source (where different from company) Company, Report No. GLP (where relevant) / (Un)published	Data Protection	Owner
A2/01	2009	Decanoic Acid: Complete Analysis of Four Batch Samples ChemService S.r.l. Study Number CH-632/2008 Unpublished	Y	SOPURA
A2.10/03	2006	Method to calculate the unavoidable residue Decanoic Acid SOPURA Unpublished	Y	SOPURA
A2.10/04	2006	Quantitative Evaluation Decanoic Acid Quantity likely to be found back in the Environment after Application SOPURA Unpublished	Y	SOPURA
Company statement	2010	INFORMATION FOLLOWING THE REQUEST FROM THE AUSTRIAN RMS (information regarding calculations)	Y	SOPURA
A3/01D	1999	Determination of some physico-chemical properties of Decanoic acid TNO Prins Maurits Laboratory PML 1999-C110 Unpublished	Y	SOPURA
A3/02D	1999	Expert statement: hydrolysis and dissociation constants of n- octanoic acid and n-decanoic acid TNO Voeding, report number V99.846 Unpublished	Y	SOPURA
A3/03rev09	2008	Decanoic Acid Determination of the bulk density Sopura, Study nr 5474-DECA- 5 Unpublished	Y	SOPURA
A3/03a	2008	Analysis report: Surface tension of Decanoic acid SOPURA, Unpublished	Y	SOPURA
A3/03b	2008	Decanoic Acid Determination of the Viscosity Sopura Study nr 5474-DECA-2 Unpublished	Y	SOPURA
A3/04	2006	Calculation of the Henry Law Constant and Log Kow Unpublished	Y	MCF- Consultancy GmbH
A3/05rev09	2008	Decanoic Acid Determination of some Physico-Chemical Properties Study nr 5474-DECA-4 Sopura Unpublished	Y	SOPURA

A3/06	2006	Expert statement Stability of decanoic acid in organic solvents Unpublished	Y	MCF- Consultancy GmbH
A3/07_rev	2008	Expert statement Thermal stability of decanoic acid Unpublished	Y	MCF- Consultancy GmbH
A3/08	2006	Expert statement Flammability , including auto flammability and identity of combustion product of decanoic acid Unpublished	Y	MCF- Consultancy GmbH
A3/12	2006	Expert statement Explosive properties of decanoic acid Unpublished	Y	MCF- Consultancy GmbH
A3/13	2006	Expert statement Oxidizing properties of decanoic acid Unpublished	Y	MCF- Consultancy GmbH
A3/14	2006	Expert statement Reactivity of decanoic acid towards container material Unpublished	Y	MCF- Consultancy GmbH
A3/15	2006	Expert statement Approval certificates Unpublished	Y	SOPURA
A3/16	2006	Edenor C 10 98-100 (decanoic acid): Determination of the water solubility considering also the effects of temperature and pH value ChemService S.r.l. Study nr CH-334/2006 Unpublished	Y	SOPURA
A3/17	2009	Decanoic Acid: Determination of the Solubility in organic Solvents considering also the Effect of Temperature ChemService S.r.l. Study nr CH-629/2008 Unpublished	Y	SOPURA
A3/18	2009	Decanoic Acid: Determination of the Flash Point ChemService S.r.l. Study nr CH-628/2008 Unpublished	Y	SOPURA
A3/18a	2009	Amendment Decanoic Acid: Determination of the Flash Point ChemService S.r.l. Study nr CH-628/2008 Unpublished	Y	SOPURA
A4.1/01	2009	Decanoic Acid: Validation of the Analytical Method for the Determination of the Active Ingredient Content ChemService S.r.l. Study nr CH-630/2008 GLP Unpublished	Y	SOPURA
A4.1/02	2008	Decanoic Acid: Validation of the Analytical Method for the Determination of the Significant Impurity Content ChemService S.r.l.	Y	SOPURA

		Study nr CH-631/2008 GLP Unpublished		
A4.2/01a	1998	In-situ methylation of strongly polar organic acids in natural waters supported by ion-pairing agents for headspace GC- MSD analysis; Dresden University of technology Fresenius J Anal Chem (1998) 361:318-323 no GLP Published	N	SOPURA
A4.2/01b	2006	Methodenvalidierung 0,1 µg/L for decanoic acid and octanoic acid Böhler Analytik Ges.m.b.H no GLP Unpublished.	Y	SOPURA
A4.3/01	2006	Food occurrence / Risk assessments Gubler-Coaching, Pfäffikon, Switzerland no GLP Unpublished	Y	MCF- Consultancy GmbH
A4.3/02	2006	Method to calculate the unavoidable residue SOPURA, Unpublished	Y	SOPURA
A4.3/03	2006	Quantitative evaluation decanoic acid quantity likely to be found back in the environment after application SOPURA Unpublished	Y	SOPURA
A4.3/04	1990	Method for the Quantitative Analysis of Volatile Free and Total Branched-Chain Fatty Acids in Cheese and Milk Fat Kim J.H.A. and Lindsay R.C. J. Dairy Sci 73:1988-1999 Published	N	Published
A4.3/05	1990	Determination of Free Fatty Acids in Wort and Beer De Vries K ASBC Journal Published	N	Published
A4.3/06	1994	Analysis of Free Fatty Acids, Fusel Alcohols, and Esters in Beer: An Alternative to CS2 Extraction J. Am. Soc. Brew. Chem. 52(3):127-134 Alvarez P. and Malcorps P Published	N	Published
A4.3/07	1985	The Semi-Routine Use of Capillary Gas Chromatography for Analysis of Aroma Volatiles in Beer ASBC Journal:203-208 Stenroos L.E. et.al Published	N	Published
A4.3/08	1990	Extraction and Analysis of Volatile Compounds in White Wines Using Amberlite XAD-2 Resin and Capillary Gas Chromatography	Ν	Published

		Edwards C.G. and Beelman R.B		
		J. Agric. Food. Chem. 38:216-220		
		Published		
A5/01	2006	Microbiological performance of SEPTACID BN on beer spoiling bacteria Unpublished	Y	SOPURA
A5.3_1/01D	2006	SOPURSEPT BN-10 + DT 6 in clean conditions report assay Haute école Lucia de Brouckère-Institut Meurice-Laboratoire de Microbiologie Unpublished	Y	SOPURA
A5.3_1/02D	2006	SOPURSEPT BN-10 + DT 6 in dirty conditions report assay	Y	SOPURA
		Haute école Lucia de Brouckère-Institut Meurice-Laboratoire de Microbiologie Unpublished		
A5.3_2/01D	2006	SOPURSEPT BN-10 + DETAL HP in clean conditions report assay	Y	SOPURA
		Haute école Lucia de Brouckère-Institut Meurice-Laboratoire de Microbiologie Unpublished		
A5.3_2/02D	2006	SOPURSEPT BN-10 + DETAL HP in dirty conditions report assay Haute école Lucia de Brouckère-Institut Meurice-Laboratoire de Microbiologie	Y	SOPURA
A5.3_3/01D	2006	SOPURSEPT BN-10 + ATR F in clean conditions report	Y	SOPURA
		Haute école Lucia de Brouckère-Institut Meurice-Laboratoire de Microbiologie Unpublished		
A5.3_3/02D	2006	SOPURSEPT BN-10 + ATR F in dirty conditions report assay Haute école Lucia de Brouckère-Institut Meurice-Laboratoire de Microbiologie Unpublished	Y	SOPURA
A5.3_2/03D	2006	SOPURSEPT BN-10 + ATR B in clean conditions report assay Haute école Lucia de Brouckère-Institut Meurice- Laboratoire de Microbiologie Unpublished	Y	SOPURA
A5.3_2/04D	2006	SOPURSEPT BN-10 + ATR B in dirty conditions report assay Haute école Lucia de Brouckère-Institut Meurice- Laboratoire de Microbiologie Unpublished	Y	SOPURA
A5.3.4/01D	2010	SEPTACID BN without A.S.: Evaluation of the bactericidal and fungicidal activity according to the European standard test method EN1276 and EN1650.	Y	SOPURA

		Haute école Lucia de Brouckère-Institut Meurice-Laboratoire		
		ue Microbiologie		
A5.3.4/02D	2010	SEPTACID BN-PS without A.S.: Evaluation of the bactericidal and fungicidal activity according to the European standard test method EN1276 and EN1650.	Y	SOPURA
		Haute école Lucia de Brouckère-Institut Meurice-Laboratoire de Microbiologie		
		Unpublished		
A5.3.4/03D	2010	Decanoic acid.: Evaluation of the bactericidal and fungicidal activity according to the European standard test method EN1276 and EN1650.	Y	SOPURA
		Haute école Lucia de Brouckère-Institut Meurice-Laboratoire de Microbiologie		
				~
A6/ 01	1976	Safety studies on a series of fatty acids.	N	Published
		American Industrial Hygiene Association Journal; April, 1976 Published		
A6/02	1962	Range-finding toxicity data: List IV	N	Published
		Smyth Jr.H.F., Carpenter C.P., Weil C.S., Pozzani U.C. and Striegel J.A.		
		American Industrial Hygiene Association Journal (AIHAJ), 23, 95-107		
		Published		
A6/03	1979	Capric acid, Opdyke D.L.J.	N	Published
		Fd Cosmet. Toxicol. 17 735 (review article) Published		
A6/04a	1996	Toxicity Profile, n-Decanoic acid (and its sodium and potassium salts)	N	Published
		TNO BIBRA Published		
A6/04b	1988	Toxicity Profile, n-Octanoic acid (and its sodium and potassium salts) TNO BIBRA Published	Ν	Published
A6/05	2006	Riskassessments	Y	MCF-
		Gubler-Coaching, Pfäffikon, Switzerland Unpublished		Consultancy GmbH
A6/07	1998	Safety evaluation of certain food additives and contaminants, saturated aliphatic acyclic linear primary alcohols, aldehydes, and acids	N	Published
		the forty-ninth meeting of the JECFA, Joint FAO/WHO Expert Committee on Food Additives		
A6/08	2004	19,71 kg Käse ass Herr Schweizer im 2004 Anonymus Internet	N	Published

A6/09	2004	Sojaöl Spychiger Oil Trading AG CH-6045 Meggen	Ν	Published
		spychiger on maning mo, en oo ie meggen		
A6/10	2002	Fettsäurezusammensetzung wichtiger pflanzlicher und tierischer Speisefette und –öle Deutsche Gesellschaft für Fettwissenschaft	N	Published
A6/11	1999	Review of the Toxicologic Properties of Medium-chain Triglycerides Traul K.A., Driedger A., Ingle D.L., Nakhasi D. Food and Chemical Toxicology 38 (2000) Published	N	Published
A6/12	1982	Medium-chain triglycerides: an update Bach A.C., Babayan V.K. The American Journal of Nutrition 36 pages 950 – 962 Published	N	Published
A6/13	2005	Evaluation of certain food additives 63 report of the Joint FAO/WHO Expert Committee on Food Additives	N	Published
A6/14	2000	http://ecb.jrc.ec.europa.eu/esis/index.php IUCLID entry	Y	Published
A6/15	2004	A chemical dataset for evaluation of alternative approaches to skin-sensitization testing Gerberick G.F. et al. Contact Dermatitis, Vol 50, No 5, 2004 Published	N	Published
A6/16	1976	SAFETY STUDIES ON A SERIES OF FATTY ACIDS. Briggs G.B., Doyle R. L., Young J. A. American Industrial Hygiene Association Journal; April 1976	N	published
A6/17	1953	Production of gastric lesions in the rat by the diet containing fatty acids Mori K. GANN, Vol. 44; December Published	N	Published
A6/18	2007	ALTERNATIVE APPROACHES TO IMMUNOTOXICITY AND ALLERGY TESTING Presentation at EUROTOX Congress 2007 unpublished	N	unpublished
A6.1.1/01	1981	Prüfung der akuten oralen Toxizität Henkel, Düsseldorf	Y	Cognis (LoA available)

A6.1.2/01	2006	Decanoic acid: Acute Dermal Toxicity Study in Rats;	Y	SOPURA
		RCC Ltd, Itingen Switzerland		
		Study Number A86556		
		Unpublished		
A6.1.3/02	1998	THE BIOPESTICIDE MANUAL	Ν	Published
		Copping L.G.		
		British Crop Protection Council, 1st edition, p. 25		
		Report-No. not applicable		
		Not GLP, Published		
A6.1.3/03		TOXICOLOGICAL SIMILARITY OF STRAIGHT CHAIN SATURATED FATTY ACIDS OF GREATER THAN 8 CARBON CHAIN LENGTH BY VARIOUS ROUTES OF EXPOSURE	N	Published
		Anonymous		
		Safer Inc, Eden Prairie MN 55334-3585, USA		
		Report-No. not applicable		
		Not GLP, Published		
A6.1.4.s/02	1999	A two-center study of the development of acute irritation responses to fatty acids.	N	Published
		Robinson M.K., Whittle E. and Basketter D.A.		
		American Journal of Contact Dermatitis, Vol. 10, No 3 1999		
		Published		
A6.1.5/2	2006	Skin Sensitisation Study (Local Lymph Node Assay); Austrian Research Centers GmbH – ARC Life Sciences Toxicology, Seibersdorf, Austria;	Y	SOPURA
		Report Nr: ARC-L2241;		
		Unpublished		
A6.1.5/1	2004	A chemical dataset for evaluation of alternative approaches to skin-sensitization testing	Ν	Published
		Gerberick G.F. et al		
		Contact Dermatitis, Vol 50, No 5, 2004		
		Published		
A6.4.1.1/01	1993	A 91-day feeding study in rats with caprenin	N	Published
		Webb D.R., Wood F.E., Bertram T.A. and Fortier N.E.		
		Fd Chem. Tox. Vol 31, No 12		
		The Proctor & Gamble Company		
		Published		
A6.4.1.1/02 A6.8.2	1968	Nutritional Evaluation of Medium-Chain Triglycerides in the Rat	N	Published
		Harkins R.W. and Sarett H.P.		
		The Journal of the American Oil Chemists' Society		
		Department of Nutritional Research, Mead Johnson Research		
		Center, Evansville, Indiana		
A6.6.1/1	1999a	Bacterial reverse mutation test with decanoic acid Netherlands Organisation for applied scientific research (TNO), Zeist, The Netherlands	Y	SOPURA

		TNO-report V99.668		
		Ref nr A6.6.1/01		
A6.6.1/2	1999b	Bacterial reverse mutation test with octanoic acid Netherlands Organisation for applied scientific research (TNO) Zeist, Netherlands TNO-Report V99.668	Y	SOPURA
A6.6.2/1	1999a	Chromosomal aberration test with decanoic acid in cultured Chinese hamster ovary cells Netherlands Organisation for applied scientific research (TNO), Zeist, The Netherlands TNO-report V99.661 Ref nr A6.6.2/01	Y	SOPURA
A6.6.2/2	1999b	Chromosomal aberration test with octanoic acid in cultured Chinese hamster ovary cells Netherlands Organisation for applied scientific research (TNO) Zeist, Netherlands TNO-Report V99.660.	Y	SOPURA
A6.6.3/1	1999a	Gene mutation test at the TK-locus of L5178Y cells with Decanoic acid; Netherlands Organisation for applied scientific research (TNO), Zeist, The Netherlands TNO-report V99.715 Ref nr A6.6.3/01	Y	SOPURA
A6.6.3/2	1999b	Gene mutation test at the TK-locus of L5178Y cells with Octanoic acid Netherlands Organisation for applied scientific research (TNO) Zeist, Netherlands TNO-Report V99.715	Y	SOPURA
A6.8.1/01	1994	Pharmacokinetic Determinats of Embryotoxicity in Rats Associated with Organic Acids Scott et al. Environmental Health Perspectives 102 (suppl 11) Published	N	Published
A6.8.1/02	1993	Pharmacokinetics and pharmacodynamics of valproate analogs in rats. II. Pharmacokinetics of octanoic acid, cyclohexanecarboxylic acid, and 1-methyl-1- cyclohexanecarboxylic acid Mei-JenLiu and Pollack G. M. Biopharmaceutics & Drug Disposition, vol. 14 Published	N	Published
A6.8.2 A6.4.1.1/02	1968	Nutritional Evaluation of Medium-Chain Triglycerides in the Rat Harkins R. W. and Sarett H. P. The Journal of the American Oil Chemists' Society Department of Nutritional Research, Mead Johnson Research Center, Evansville, Indiana Published	N	Published
A7.1.1.2.1/0	2005	Fragrances and Biodegradation Göteborgs Stad Miljö ISSN 1401-2448 ISRN GBG-M-R—05/05—SE	N	Published

		Published		
A7.1.1.2.1/0 2	2006	DECANOIC ACID: READY BIODEGRADABILITY IN A MANOMETRIC RESPIROMETRY TEST; RCC LTD, Itingen, Switzerland; RCC Study Number: A86567 Unpublished	Y	SOPURA N.V.
A7.1.3/01	2008	ADSORPTION/DESORPTION OF DECANOIC ACID ON SOILS; RCC Ltd, Itingen; RCC Report No. A86466 Unpublished	Y	SOPURA N.V.
A7.4.1.1/01	2001	Decanoic acid – fish, Acute Toxicity, Final Report R-0100702 Henkel KgaA Department of Ecology Unpublished	Y	COGNIS Deutschland GmbH (LoA available)
A7.4.1.1/02 O	2006	Octanoic Acid: Acute Toxicity to Zebra Fish (Brachydanio Rerio) in a 96-hour semi-static Test RCC Ltd; Itingen, Switzerland RCC Study Number A86501	Y	SOPURA
A7.4.1.1/03 O	2006	First Amendment to Study Plan Octanoic Acid: Acute Toxicity to Zebra Fish (Brachydanio Rerio) in a 96-hour semi-static Test RCC Ltd; Itingen, Switzerland RCC Study Number A86501	Y	SOPURA
A.7.4.1.2/01	2006	DECANOIC ACID: ACUTE TOXICITY TO DAPHNIA MAGNA IN A 48-HOUR IMMOBILIZATION TEST; RCC Ltd, Itingen, Switzerland; RCC Study Number: A86488 Unpublished	Y	SOPURA
A7.4.1.3/01	2008	DECANOIC ACID: TOXICITY TO SCENEDESMUS SUBSPICATUS IN A 72-HOUR ALGAL GROWTH INHIBITION TEST; RCC Ltd, Itingen, Switzerland RCC Study Number: A86523 (inclusive A86534) Unpublished	Y	SOPURA
A7.4.1.4/01	2006	DECANOIC ACID: TOXICITY TO ACTIVATED SLUDGE IN A RESPIRATION INHIBITION TEST; RCC Ltd, Itingen Switzerland; RCC Study Number A86545 Unpublished	Y	SOPURA N.V.
A7.4.2/01	2006	Calculation of the BCF for decanoic acid with the US-EPA program BCF Program	Y	MCF- Consultancy GmbH

## Additional Literature:

Section No / Reference No	Author	Year	Title Source Institution; report nr GLP-, GEP-status Published or unpublished	Data Protection	Owner
A.5	Cowles, P.B.	1941	The germicidal action of the hydrogen ion and of the lower fatty acids. Yale J. Biol. Med. 13:571	Ν	published
## Additional references:

Year	Title Source	Data Protectio n	Owner
	Institution; report nr		
	GLP-, GEP-status		
	Published or unpublished		
2010	Agreement regarding the transfer of test reports between Octanoic and Decanoic acid	Y	Fatty acids consortium
	Fatty acids consortium		
	No GLP		
	unpublished		
2010	Agreement regarding the transfer of documents between the product types Fatty acids consortium No GLP	Y	Fatty acids consortium
	unpublished		
2008	The COLIPA strategy for the development of in vitro alternatives: Skin sensitisation	N	published
	Aeby P., Ashikaga T., Diembeck W.,, Eschrich D., Gerberick F.,,		
	Kimber I, Marrec-Fairley M., Maxwell G., Ovigne J.M.,		
	Sakaguchi1H., Tailhardat M., Teissier S.		
	AATEX 14, Special Issue, 375-379		
	http://altweb.jhsph.edu/wc6/		
1995	Skin irritation in man: a comparative bioengineering study using improved reflectance spectroscopy	N	published
	Andersen PH, Maibach HI		
	Contact Dermatitis 33(5):315-22		
1985	Chronic mouse dermal toxicity study, test material C-182 = Pelargonic Acid Barkley W.	just EPA study	published
	Kettering Laboratory, Univ. Cincinnati, OH, U.S.A.	summary	
	Report No. not stated	, no letter	
	Not GLP, Published	from	
		applicant	
		available	
1997	The classification of skin irritants by human patch test Food Chem Toxicol. 35(8):845-52.	Ν	published
2007a	Does irritation potency contribute to the skin sensitization potency of contact allergens?	N	published
	Cutan Ocul Toxicol. 26(4): 279-86.		
2007b	The Local Lymph Node Assay: Current Position in the	N	published
	Regulatory Classification of Skin Sensitizing Chemicals		
	Cutaneous and Ocular Toxicology 26:4, 293 - 301		
1998	Strategies for Identifying False Positive	N	published
	Responses in Predictive Skin Sensitization		
	Tests		
	Food and Chemical Toxicology 36: 327-333		
2005	Long-term repetitive sodium lauryl sulfate-induced irritation of the skin: an in	N	published

	vivo study.		
2006	Toxicological modes of action: relevance for human risk assessment         Technical Report No. 99, July 2006	N	published
2007	statement on the validity of in-vitro tests for skin irritation http://ecvam.jrc.it/index.htm	N	published
1992	<ul> <li>Propionic acid and the phenomenon of rodent forestomach tumorigenesis: a review</li> <li>BP group Occupational Health Centre, Guilford, Surrey, U. K</li> <li>Food Chem Toxicol. 1992 Apr; 30(4): 333-40</li> <li>Report-No. Not applicable</li> <li>Not GLP, Published</li> </ul>	N	published
1999	Predictive Value of Rodent Forestomach and Gastric Neuroendocrine Tumours in Evaluating Carcinogenic Risks to Humans IARC Technical Publication No. 39, 1999	N	published
2007	Comparison of human skin irritation and photo-irritation patch test data with cellular in vitro assays and animal in vivo data AATEX 14, Special Issue, 359-365; Proc. 6th World Congress on Alternatives & Animal Use in the Life Sciences; August 21-25, 2007, Tokyo, Japan <u>http://altweb.jhsph.edu/wc6/paper359.pdf</u>	N	published
2008	Comparison of the skin sensitizing potential of unsaturated compounds as assessed by the murine local lymph node assay (LLNA) and the guinea pig maximization test (GPMT) Kreiling R., Hollnagel H.M., Hareng L., Eigler D., Lee M.S., Griem P., Dreeßen B., Kleber M., Albrecht A, Garcia C., Wendel A. Food Chem Toxicol. 46(6): 1896-1904	N	published
2008	Analysis of differential gene expression in auricular lymph nodes draining skin exposed to sensitizers and irritants Ku HO, Jeong SH, Kang HG, Pyo HM, Cho JH, Son SW, Ryu DY Toxicol Lett. 177(1):1-9.	N	published
2008	Skin sensitization in chemical risk assessment: report of a WHO/IPCS international workshop focusing on dose-response assessment Loveren van H, Cockshott A, Gebel T, Gundert-Remy U, de Jong WH, Matheson J, McGarry H, Musset L, Selgrade MK, Vickers C. Regul Toxicol Pharmacol. 50(2):155-99.	N	published
2007	McLean J. et al. Journal of Chemical Ecology 33:1997-2009	N	published
1998	Murine local lymph node assay for predictive testing of allergenicity: two irritants caused significant proliferation. Montelius J, Wahlkvist H, Boman A, Wahlberg JE. Acta Derm Venereol. 78(6): 433-7	N	published
2002	Subacute 28-Day Oral toxicity with Pelagonsäure by Daily Gavage in the Rat Notox B.V, 's-Hertogenbosch, The Netherlands Report-no. 321582 GLP, Unpublished	Y	W. Neudorff GmbH KG
2001a	Assessment of Acute oral Toxicity with Pelargonsäure in the Rat (Acute Toxic	Y	W.

	Class Method)		Neudorff
	Notox B.V, 's-Hertogenbosch, The Netherlands		GmbH KG
	Report-No. 321547		
	GLP, Unpublished		
2001b	Assessment of Acute Dermal Toxicity with Pelargonsäure in the Rat	Y	W.
	Notox B.V, 's-Hertogenbosch, The Netherlands		Neudorff
	Report-No. 321558		GINDH KG
	GLP, Unpublished		
2007	Mode-of-action framework for evaluating the relevance of rodent forestomach tumors in cancer risk assessment.	N	
	Proctor DM, Gatto NM, Hong SJ, Allamneni KP.		
	Toxicol Sci. 98(2):313-26		
	Report-No. Not applicable		
	Not GLP, Published		
2001	Validity and ethics of the human 4-h patch test as an alternative method to assess acute skin irritation potential	N	published
	Robinson MK, McFadden JP, Basketter DA.		
	Contact Dermatitis 45(1):1-12		
1991	Schilder M.	N	published
	Applied Animal Behaviour Science, 32:227-236		_
2007	The ECVAM international validation study on in vitro tests for acute skin irritation: report on the validity of the EPISKIN and EpiDerm assays and on the Skin Integrity Function Test.	N	published
	Spielmann H, Hoffmann S, Liebsch M, Botham P, Fentem JH, Eskes C, Roguet R, Cotovio J, Cole T, Worth A, Heylings J, Jones P, Robles C, Kandárová H, Gamer A, Remmele M, Curren R, Raabe H, Cockshott A, Gerner I, Zuang V.		
	Altern Lab Anim. 35(6):559-601		
2003	Nonanoic acid – an experimental irritant	Ν	published
	Wahlberg J, Lindberg M.		
	Contact Dermatitis 49: 117–123		
1983	Assessment of skin irritancy: measurement of skin fold thickness	Ν	published
	Wahlberg JE		
	Contact Dermatitis 9(1):21-6		
1980	Nonanoic acid irritation - a positive control at routine patch testing?	N	published
	Wahlberg JE, Maibach HI		
	Contact Dermatitis 6(2):128-30		
1985	Skin irritancy from nonanoic acid	N	published
	Wahlberg JE, Wrangsjö K, Hietasalo A.		-
	Contact Dermatitis 13(4):266-9		
1988	Forestomach carcinogens: pathology and relevance to man.	N	published
	National Institute of Public Health and Environmental Protection, Bilthoven, The Netherlands		1
	Wester PW., Kroes R.		
	Toxicol Pathol. 1988; 16(2): 165-71		
	Report-No. Not applicable, Not GLP, Published		
2005	Guidance document for the use of data in development of chemical-specific		
	adjustment factors (CSAFs) for interspecies differences in human variability in		

	dose/concentration-response assessment.		
	WHO/IPCS		
	IPCS harmonization project document ; no. 2		
	http://www.inchem.org/documents/harmproj/harmproj/harmproj2.pdf		
1988b	Assessment of erythema in irritant contact dermatitis. Comparison between visual scoring and laser Doppler flowmetry	Ν	published
	Willis CM, Stephens CJ, Wilkinson JD.		
	Contact Dermatitis 18(3):138-42		
1988a	Experimentally-induced irritant contact dermatitis. Determination of optimum irritant concentrations	N	published
	Willis CM, Stephens JM, Wilkinson JD		
	Contact Dermatitis 18(1):20-4.		
1996	Evaluation of a human patch test for the identification and classification of skin irritation potential.	N	published
	York M, Griffiths HA, Whittle E, Basketter DA.		
	Contact Dermatitis 34(3):204-12.		
2001c	Primary Skin Irritation/Corrosion Study with Pelargonsäure in the Rabbit (4- Hour Semi-Occlusive Application)	Y	W. Neudorff
	Notox B.V, 's-Hertogenbosch, The Netherlands		GmbH KG
	Report-no. 321604		
	GLP, Unpublished		
2001d	Assessment of Contact Hypersensitivity to Pelargonsäure in the Albino Guinea Pig (Maximisation-Test)	Y	W. Neudorff
	Notox B.V, 's-Hertogenbosch, The Netherlands		GmbH KG
	Report-no. 321615		
	GLP, Unpublished		
2003	The National Diet and Nutrition Survey: Adults Aged 19-64 years, Volume 2: Energy, protein, carbohydrate, fat and alcohol intake.	N	
	Henderson L., Gregory J., Irving K., Swan G.		
	London, HMSO		
2006	The National Diet and Nutrition Survey: Adults Aged 19-64 years, Volume 4: Nutritional status (anthropometry and blood analytes), blood pressure and physical activity.	Ν	
	Ruston D., Horare J., Henderson L., Gregory J., Bates C.J., Prentice A., Birch M., Swan G., Farron M.		
	London, HMSO.		

## 8 ANNEXES

Confidential Annex.